Stockwinners Market Radar for February 22, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:41 EST Cathie Wood's ARK Investment bought 24.4K shares of Tesla today

20:38 EST Cathie Wood's ARK Investment bought 115K shares of Zoom Video today

18:35 EST Overstock.com jumps 9.6% to $39.93 after ICE announced investment in tZero

18:08 EST Capcom unveils 'Street Fighter 6' - Capcom announced yesterday that "Street Fighter 6." The company did not produce any details about the game or provide a release date, but noted that more information about the game is coming this summer. Reference Link

17:37 EST Moderna announces Latin America distribution partnership with Adium Pharma - Moderna announced a distribution service agreement with Adium Pharma S.A., a private Latin American pharmaceutical company, to support the commercialization of the Moderna COVID-19 vaccine, Spikevax across Latin America. The agreement covers 18 countries in Latin America, including Brazil, Mexico, Colombia, and Argentina. "Our new partnership with Adium will help ensure broad access and delivery of our Moderna COVID-19 vaccine to people across Latin America," said Stephane Bancel, Chief Executive Officer of Moderna. "A presence in Latin America is a key part of our global commercial strategy. These partnerships and the expansion of our global commercial footprint position Moderna to play an important role in providing healthcare security against COVID-19 and future vaccine-preventable diseases." Moderna has a commercial presence in 11 countries worldwide (Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, Switzerland, UK, U.S.) and recently announced plans to increase its commercial footprint across ten additional markets in Asia-Pacific (Hong Kong, Malaysia, Singapore, Taiwan) and Europe (Belgium, Denmark, the Netherlands, Norway, Poland, Sweden) in 2022. The Company also has commercial agreements with distributors to supply the Company's COVID-19 vaccine in 45 countries, with Zuellig Pharma in the Asia Pacific, Medison Pharma in Central Eastern Europe and Israel, and Adium Pharma in Latin America. In addition, Moderna announced an agreement with Gavi, the Vaccine Alliance, to supply up to 650 million doses of the Company's COVID-19 Vaccine across 2021 and 2022, covering the 92 Gavi COVAX Advance Market Commitment (AMC) low- and middle-income countries.

17:29 EST Caesars says will curtail media spend effective immediately - Says omicron nipped the company in the bud in the last two weeks of the year. Says omicron continued to impact occupancy in January. Says got a good setup in Vegas going forward. Says hoping New Orleans restrictions go away post Mardi Gras. Says in all states reporting sports betting revenue, the company has 21% of sports betting market in U.S. Says next step is moving toward profitability. Says will curtail media spend effective immediately. Says will see commercials largely disappear from screens. Says largely off traditionally media except with the launch in new states from here. Says New York volumes and market share were two times higher than expectations. Says this quarter is peak EBITDA loss. Comments taken from Q4 earnings conference call.

17:26 EST Pangaea Logistics names Mads Boye Petersen as new COO - Pangaea Logistics announced that Mads Boye Petersen has been appointed its COO, effective on April 1, 2022. Petersen replaces Mark Filanowski, who was promoted to CEO of Pangaea in December 2021. As Chief Operating Officer, Mr. Petersen will have broad responsibilities, including group strategy and execution, as well as capital market and ESG initiatives.

17:10 EST Lee Enterprises 'disappointed, but not surprised' by Alden Global lawsuit - Lee Enterprises issued the following statement in response to the recent lawsuit filed by Alden Global Capital LLC in the Delaware Court of Chancery: "We are disappointed, but not surprised, that Alden continues to pursue increasingly desperate measures in an attempt to destabilize Lee and advance its grossly undervalued hostile proposal to purchase the Company. We are applying the clear and plain language of our bylaws, which is not new, and our position that plurality voting applies at this meeting (because of Alden's actions) has been abundantly clear in our disclosures for over a month now. Alden asked us last week to amend our bylaws to change the clear meaning of them in the middle of an election. The Board properly determined not to do so." Lee's Board urges shareholders to protect their investment by voting "FOR" ALL the Board's nominees using the WHITE proxy card. All shareholders at the close of business on January 12, 2022 are entitled to vote at the Annual Meeting.

17:01 EST Sigilon Therapeutics appoints Sarah Yuan as chief technical operations officer - Sigilon Therapeutics announced the appointment of Sarah Yuan as chief technical operations officer, effective March 7. Yuan brings more than 20 years of experience in process development, manufacturing sciences and CMC strategies from a broad range of leading biopharmaceutical companies.

17:01 EST View Inc. reaffirms expectation to complete financial restatements - View, Inc. reaffirmed the company's expectation to issue its restated 2019, 2020 and Q1 2021 financial statements, as well as its Q2 2021, Q3 2021 and full year 2021 financial statements in the first quarter of 2022. As expected, View received a Staff Delisting Determination from the Listing Qualifications Department of The Nasdaq Stock Market LLC. On February 22, 2022, the Company appealed the Staff Determination by requesting a hearing before a Nasdaq Hearings Panel to present its plan to regain compliance with the applicable listing requirements. Under Nasdaq Listing Rules, such request automatically stays the suspension of the Company's securities for a period of 15 days from the date of the request. In connection with its request for a hearing, the Company has also requested that the suspension and delisting of its common stock be further stayed pending the hearing and a decision of the Hearings Panel. According to the Staff Determination, hearings are typically scheduled to occur approximately 30-45 days after the date of a Company's hearing request. Completing financial restatements as well as releasing quarterly and annual filings detailed above would regain compliance with applicable NASDAQ listing requirements.

16:58 EST Mosaic announces new $1B share repurchase program, dividend raise in Q2 - Mosaic anticipates returning the majority of free cash flow to shareholders in 2022. The company believes up to 75% of free cash flow will be distributed to shareholders through a combination of dividends and share repurchases. Mosaic expects to initiate an accelerated share repurchase of $400M in February. Following execution of the ASR, Mosaic will have repurchased approximately $830M under the current $1B authorization established in August 2021. Mosaic expects to exhaust the remaining portion of the current authorization through open market purchases. As a result, the Mosaic Board of Directors has approved the establishment of a new $1B share repurchase authorization, which will take effect immediately following completion of the current program. The Mosaic Board of Directors has also approved a regular dividend target increase to 60c per share annually from 45c, beginning with the second quarter payment.

16:56 EST Whitestone REIT raises annual cash dividend by 11.6% - Whitestone REIT announced that its Board of Trustees has declared a monthly cash dividend on the Company's common shares, increasing the monthly dividend rate to 4c per share, up from 03.5833c per share. The dividend increase represents a quarterly amount of 12c per share, and an annualized amount of 48c per share, up 11.6% from the previous annualized level of $0.43 per share. "At Whitestone, we are successfully executing on our growth strategy and improving the Company's financial and operational performance to deliver even greater returns for shareholders," said Dave Holeman, Whitestone's CEO. "This dividend increase reflects the Board's confidence in the underlying strength of Whitestone and its assets, its talented employees and new management team, and bright prospects for sustainable growth and value creation. We are proud of our improving results and cash flow generation and look forward to building and reporting on our progress."

16:50 EST Marrone Bio appoints LaDon Johnson interim CFO amid Cheung resignation - Marrone Bio Innovations announced a transition of its Chief Financial Officer role. Current CFO Sue Cheung has chosen to resign for personal reasons, effective March 9 . LaDon Johnson, a director with CFO Systems, has been appointed interim CFO on a consulting basis while the company begins a national search for a permanent CFO. "We appreciate Sue's contributions to Marrone Bio over the past year, and wish her the best," said Chief Executive Officer Kevin Helash. "I have full confidence in LaDon and our finance organization, and expect the transition to be seamless." Johnson has more than 30 years of experience in global corporate finance in the agriculture, food, renewables and biotechnology sectors. Previous roles include serving as CFO for an international biotechnology company and as Managing Director and CFO for the fifth largest crop seed company in the world.

16:47 EST Exponent board approves a $150M expansion of share repurchase pact - Exponent announced that its Board of Directors approved a $150M expansion of its share repurchase program, adding to the $29.5 million that remains available under the current authorization for repurchases. In total, the Company now has approximately $179.5 million available to repurchase shares. The Company has repurchased $38.9 million of common stock in fiscal year 2022. "Today's announcement, combined with the recent 20% increase in our quarterly dividend, reflects our unwavering confidence in Exponent's strategic direction and our commitment to delivering long-term value for our shareholders," commented Dr. Catherine Corrigan, President and Chief Executive Officer. "Exponent's balanced capital allocation strategy includes investing in initiatives to drive long-term profitable growth while also returning cash to shareholders through dividends and repurchases. This is supported by our consistent cash flow and strong financial position, including that we ended fiscal 2021 with $297.7 million in cash and cash equivalents."

16:46 EST Range Resources expands share repurchase program by $500M - Range's board of directors approved an expansion of the company's share repurchase program with $500M available and effective immediately. This repurchase program, which is equivalent to approximately 10% of Range's market capitalization, is expected to be funded with free cash flow generation.

16:45 EST Texas Roadhouse boosts dividend to 46c per share - On February 17 the Board of Directors authorized the payment of a quarterly cash dividend of $0.46 per share of common stock. This payment will be distributed on March 25, 2022, to shareholders of record at the close of business on March 9, 2022.

16:43 EST Fuel Tech awarded air pollution control orders totaling $5.3M - Fuel Tech announced the receipt of multiple air pollution control contracts from customers in India, South Africa, the US, and China. These awards have an aggregate value of approximately $5.3M. Vincent J. Arnone, President and Chief Executive Officer, commented, "We are pleased to announce these contract awards including our first Fuel Tech Flue Gas Conditioning systems in India along with our first electrostatic precipitator upgrade in South Africa. These awards represent the breadth of Fuel Tech's technology solutions that can be provided to a wide range of end markets, fuels, processes and geographies. We are excited to be supporting the needs of both new customers and existing end users. We have begun to see activity in our markets increase with the improved economic outlook as the effects of the COVID-19 pandemic subside."

16:37 EST Verisk Analytics boosts dividend 6.9% to 31c per share - On December 31, 2021, we paid a cash dividend of 29 cents per share of common stock issued and outstanding to the holders of record as of December 15, 2021. On February 16, 2022, our Board of Directors approved a 6.9% increase in our cash dividend to 31 cents per share of common stock issued and outstanding, payable on March 31, 2022, to holders of record as of March 15, 2022.

16:34 EST Lument Finance Trust raises $83.5M in rights offering - Lument Finance Trust announced the final results of its transferable rights offering, which entitled holders of rights to purchase one share of common stock for every right held at a subscription price of $3.06 per share. The rights offering expired on February 11 at 5:00 p.m., New York City time. The company received subscription requests for 27,277,269 shares of common stock. Accordingly, the company raised aggregate gross proceeds of approximately $83.5M in the rights offering. The company issued the 27,277,269 shares of common stock subscribed for in the rights offering on February 22. The company intends to use the net proceeds from the sale of shares of its common stock in the rights offering to acquire or originate commercial real estate mortgage loans in accordance with the company's investment strategy and for other general corporate purposes.

16:32 EST Amerisafe raises quarterly dividend 6.9% to 31c per share - Amerisafe announced that its Board of Directors has increased the quarterly dividend by 6.9%, from 29c to 31c per share. The Board of Directors declared a quarterly cash dividend of 31c per share, payable on March 25, 2022 to shareholders of record as of March 11, 2022.

16:29 EST Palo Alto Networks jumps 6% to $503. after Q2 results beat, FY22 guidance raised

16:24 EST Virgin Galactic sees Q1 free cash flow of ($85M) to ($75M)

16:23 EST Ingles Markets names Patricia Jackson CFO - Ingles Markets announced the promotion of Patricia (Pat) E. Jackson to Chief Financial Officer (CFO) effective February 23, 2022. Pat will replace Ronald B. Freeman who recently retired as CFO. "We are proud to promote Pat Jackson as our new CFO. We look forward to her effective leadership and sound judgment helping us maintain our strong financial posture," said Robert P. Ingle II, Chairman of the Board.

16:22 EST Eros STX Global receives NYSE extension for delayed annual report - Eros STX Global Corporation announced that the New York Stock Exchange granted the Company an extension through May 31, 2022, subject to reassessment on an ongoing basis, to complete and file with the Securities and Exchange Commission its annual report on Form 20-F for the fiscal year ended March 31, 2021 and any subsequent delayed filings. The NYSE notified the Company that it will closely monitor the Company's progress with the interim milestones the Company previously submitted to the NYSE. Failure to achieve these interim milestones could result in an accelerated trading suspension prior to May 31, 2022. The NYSE separately notified the Company that it regained compliance with the NYSE's minimum trading price requirement. The Company regained compliance as of February 21, 2022 because the closing share price for its common stock was above $1.00 and its average closing share price over the preceding consecutive 30 trading-day period was also above $1.00. In the event the Company again falls below thresholds, the Company will be subject to immediate review by the NYSE.

16:20 EST Hamilton Beach announces $25M share repurchase plan - The Board of Directors approved a stock repurchase program providing for the purchase of up to $25M of the company's outstanding Class A Common Stock effective immediately and running through December 31, 2023. The company's previously authorized share buyback program was approved by the Board of Directors in November 2019 for the purchase of up to $25M of the company's outstanding Class A common stock through December 31, 2021. Under the company's previously authorized share buyback programs, the company has repurchased a total of 364,893 shares for a total aggregate purchase price of $6M.

16:19 EST Texas Roadhouse declares quarterly dividend of 46c per share - On February 17, the Board of Directors authorized the payment of a quarterly cash dividend of $0.46 per share of common stock. This payment will be distributed on March 25, 2022, to shareholders of record at the close of business on March 9, 2022.

16:18 EST Texas Roadhouse sees store week growth of approximately 6.5% - Comparable restaurant sales at company restaurants for the first seven weeks of our first quarter of fiscal 2022 increased 20.6% compared to 2021. Store week growth of approximately 6.5%, including the impact of the seven franchise locations acquired.

16:18 EST M&T Bank re-authorizes stock repurchase program of up to $800M - M&T Bank announced that its Board of Directors re-authorized a stock repurchase program of up to $800M of shares of common stock, 50c par value per share, on the open market or in privately negotiated transactions. The Board originally authorized the program in January 2021, but no repurchases were made in 2021 following M&T's announcement of its pending merger with People's United Financial.

16:17 EST Valmont raises quarterly dividend 10% to 55c per share - Valmont Industries announced that its Board of Directors approved an increase to its quarterly cash dividend to 55c per share, or a rate of $2.20 per share on an annualized basis. This represents an increase of 10% from the prior quarterly cash dividend of $0.50 per share. The dividend will be payable on April 15, 2022 to shareholders of record on March 25, 2022. The Company previously increased the dividend by 11% in February 2021. "After another strong year of growth and solid execution by our team, we are pleased to announce an increase in our quarterly dividend," said Stephen G. Kaniewski, President and Chief Executive Officer. "This increase reflects our commitment to a balanced capital allocation strategy and ability to consistently generate solid cash flow. We continue to strengthen our organization for the future by investing in the sustained, long-term growth of our business, both organically and through strategic acquisitions, while returning additional capital to our shareholders."

16:15 EST Bunge signs JV agreement with Chevron - Chevron U.S.A. Inc., a subsidiary of Chevron Corporation ( CVX), and Bunge North America, Inc., a subsidiary of Bunge Limited (BG) "announced the signing of definitive transaction agreements to create their previously announced joint venture. The new venture will create renewable feedstocks leveraging Bunge's expertise in oilseed processing and farmer relationships and Chevron's expertise in fuels manufacturing and marketing. The agreements are subject to customary closing conditions, including regulatory approval. Bunge's soybean processing plants in Destrehan, Louisiana and Cairo, Illinois will be contributed to the joint venture with Chevron contributing approximately $600 million in cash. Plans include approximately doubling the combined capacity of these facilities from 7,000 tons per day by the end of 2024. The joint venture may also explore opportunities in other renewable feedstocks, as well as in feedstock pretreatment."

16:06 EST Cerus backs FY22 product revenue view of $157M-$164M vs. $130.9M in FY21

15:47 EST AppTech Payments mutually terminates strategic partnership with Silver Alert - AppTech Payments announced its partnership with Silver Alert Services, dba LifeLight Services, has been terminated by mutual agreement with an effective date of Feb. 17. "The termination is due to the delayed release of LifeLight Systems, Silver Alert Services innovative and comprehensive remote patient monitoring system, due to the market effects of COVID. This partnership was initiated in August 2020 to leverage both companies' strengths while expanding AppTech's reach into the telehealth sphere. During the past years working together, AppTech and Silver Alert have developed a close working relationship and will continue to work together on projects and partnering relationships. This mutual agreement on termination will allow AppTech to focus on preparation of the launch of its highly anticipated, patented digital banking platform that will allow the company to set out on its business initiative of 'powering commerce experiences'," AppTech said.

15:03 EST Roche's Genentech receives FDA orphan designation for pralsetinib - According to a post on the FDA's website, Genentech's treatment of metastatic RET fusion-positive solid tumors, pralsetinib, received orphan designation. Reference Link

14:34 EST Lockheed Martin announces contract award with Philippine DND for 32 Black Hawks - PZL Mielec, a Lockheed Martin company, announced it has signed a contract award with the Philippine Department of National Defense, or DND, to manufacture 32 additional S-70i Black Hawk utility helicopters for the Philippine Air Force. "Delivery of all 32 aircraft by 2026 will dramatically increase the operational capacity of the Philippine Air Force to perform search and rescue missions, humanitarian assistance and disaster relief, and troop transport across the archipelagic country... The Philippine contract for 32 aircraft is the largest single order of Black Hawk helicopters for PZL Mielec since S-70i aircraft production began in 2009. The contract signing comes two months after PZL Mielec, based in southern Poland, completed deliveries of 16 S-70i Combat Utility Helicopters on schedule to the Philippine Air Force 205th Tactical Helicopter Wing in December 2021," the company said. Reference Link

13:03 EST Alden Global affiliate files lawsuit against Lee Enterprises - Alden Global said, "Alden Global Capital announced that its affiliate filed a lawsuit seeking to prevent Lee from brazenly disenfranchising shareholders by rigging the upcoming director election to guarantee the re-election of entrenched directors who have profited substantially even while the company is in a downward spiral and its journalism is suffering. After announcing in December 2021 that no valid stockholder nominations had been received, and winning a court ruling on that point, Lee is now using an illegal voting standard that prevents shareholders from meaningfully participating if they wish to vote against two deeply entrenched directors -- Mary Junck and Herbert Moloney. This year's election is of particular importance since these directors are only up every three years. Lee's nominees are clearly the only candidates up for election, but the Lee Board is falsely claiming that this year's election is 'contested' in order to use an improper 'plurality' voting standard -- ensuring re-election for nominees who receive even as little as a single vote in their favor. Alden remains committed to ensuring Lee's shareholders have the opportunity they deserve to decide if board members should be protected at all cost or forced out for doing a bad job. With this latest brazen act, Lee's self-interested Board continues to prioritize themselves over shareholders who have the right to elect directors. Alden's lawsuit is aimed at ensuring that it is Lee's shareholders who elect Lee's directors, not Lee's Board."

13:00 EST Microsoft's Bethesda to shutter Bethesda.net Launcher for PC - Bethesda, a video game publisher owned by Microsoft, said it is dropping its Bethesda.net Launcher for PC games this year. "Starting in early April you'll be able to migrate your games and Wallet to your Steam account," Bethesda said. The Fly notes that Bethesda, which was acquired by Microsoft in 2021, makes games in the "Doom," "Fallout," "Elder Scrolls," and "Wolfenstein" franchises. Reference Link

12:35 EST Sanofi's board proposes election of Carole Ferrand, Emile Voest as directors - Sanofi's Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on May 3, 2022, the renewal of the mandates of Paul Hudson, Christophe Babule, Patrick Kron and Gilles Schnepp and the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors. Melanie Lee and Carole Piwnica will leave the Board of Directors. Carole Ferrand is currently CFO of the Capgemini Group and Director of Fnac Darty. Emile Voest is currently director of Cancer Core Europe. Antoine Yver took over in 2021 as Chief Medical Officer of Centessa Pharmaceuticals. Serge Weinberg, Chairman of the Board of Directors, said: "These evolutions reflect the Board's intention to strengthen the Board of Director's expertise in science, notably in the field of oncology, and finance, while maintaining the size of the Board at 16 members [including 2 Directors representing employees]."

12:17 EST Verizon, Audi of America partner to bring 5G to vehicle lineup - Verizon Business (VZ) and Audi of America (AUDVF) announced an agreement to bring 5G connectivity to the automaker's U.S. lineup, estimated to begin with select models for the 2024 model year. The collaboration brings embedded 5G Ultra Wideband connectivity into Audi vehicles and provides the speed and telecommunication architecture necessary for highly personalized and augmented mobile services, new driver-assistance features, and connectivity-enabled innovations for the automated future of driving. The embedded technology will allow a vehicle to connect to the Verizon 5G Ultra Wideband network to enable advanced driving features, connected services, and blazing-fast in-car Wi-Fi and infotainment

12:12 EST Amazon files lawsuit against AppSally, Rebatest review brokers - Amazon has filed lawsuits against review brokers who "orchestrate the posting of incentivized and misleading product reviews, in exchange for money or free products." The lawsuits aim to shut down two major fake review brokers, AppSally and Rebatest, who helped mislead shoppers by having their members try to post fake reviews in stores such as Amazon, eBay, Walmart, and Etsy. This legal action is one part of Amazon's comprehensive and proactive efforts to ensure a safe and trustworthy shopping experience for its customers and extensive opportunities to create thriving businesses, the company said in a statement. "Fake review brokers attempt to profit by deceiving unknowing consumers and creating an unfair competitive advantage that harms our selling partners," said Dharmesh Mehta, VP of WW Customer Trust & Partner Support, Amazon. "We know how valuable trustworthy reviews are to our customers. That is why we are holding these review fraudsters accountable. While we prevent millions of suspicious reviews from ever appearing in our store, these lawsuits target the source."

12:01 EST Tempur Sealy falls -16.5% - Tempur Sealy is down -16.5%, or -$6.17 to $31.24.

12:00 EST IronNet rises 10.7% - IronNet is up 10.7%, or 40c to $4.08.

12:00 EST Meritor rises 45.9% - Meritor is up 45.9%, or $11.31 to $35.98.

11:45 EST Magna enters JV with LAN Manufacturing to assemble seats in Michigan - Magna announced it has entered into a joint venture with LAN Manufacturing, a minority-owned automotive supplier based in Michigan. The JV, to be called LM Manufacturing, will assemble complete seats for various trucks and SUVs for Ford Motor Company operating from a 296,000 square-foot leased facility in Detroit, Michigan. Magna will own a 49% stake. Production is scheduled to begin in the second quarter of 2023 and is expected to bring-in more than 390 jobs to the city of Detroit. The Michigan Strategic Fund has awarded a $2M grant to the JV.

11:39 EST Rani Therapeutics Holdings Inc (Class A Stock) trading halted, volatility trading pause

11:07 EST BioXcel announces results from Phase 3 SERENITY II trial published in JAMA - BioXcel Therapeutics announced the publication of results from its pivotal Phase 3 SERENITY II trial of BXCL501 for the acute treatment of agitation associated with bipolar disorder in the Journal of the American Medical Association, or JAMA. BXCL501 is an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine, a selective alpha-2 receptor agonist for the treatment of agitation associated with neuropsychiatric disorders. In the study, BXCL501 120 mcg and 180 mcg significantly reduced agitation compared with placebo as measured by change from baseline on the Positive and Negative Syndrome Scale-Excited Component total score at two hours after treatment. On the key secondary endpoint, sublingual dexmedetomidine demonstrated statistically significant improvement in PEC scores compared with placebo beginning as early as 20 minutes after dosing for both treatment groups. "We are pleased that JAMA's publication of these data prominently validates BXCL501 as a potential treatment for the millions of patients experiencing agitation associated with bipolar disorders. We look forward to our April 5, 2022 PDUFA date and potential FDA approval of BXCL501 for the acute treatment of agitation associated with bipolar disorders as well as schizophrenia. Building on the strength of these compelling data, we are also confidently progressing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's disease," said Frank D. Yocca, Ph.D., Chief Scientific Officer of BioXcel Therapeutics.

10:56 EST JLL appoints Nashunda Williams as head of DEI - JLL announced that Nashunda Williams has been appointed to the global role of Head of Diversity, Equity and Inclusion with responsibility for implementing the company's DEI strategy. Reporting to CEO Christian Ulbrich and working closely with external advisors, she will focus over the next 24 months on identifying comprehensive actions and assessing future leadership investments that will accelerate JLL's culture of DEI. Williams has been a leader at JLL for the past six years, first as a technology advisor for the Work Dynamics business and, most recently, as an IT business partner within JLL Technologies. Williams assumes this role from Ingrid Jacobs, who has led JLL's diversity and inclusion initiatives for the past year.

10:47 EST cbdMD requests FDA remove drug exclusion for CBD, review safety submission - cbdMD announced that the Natural Products Association filed a Citizen's Petition on cbdMD's behalf with the Food and Drug Administration requesting the FDA to remove the drug exclusion for CBD and to review the company's dossier of data. cbdMD said: "Removing the drug exclusion for CBD will achieve clarity in the market and create a level playing field for all participants. The final outcome of this process is expected to result in the ability of the Company to submit and receive acknowledgement for a New Dietary Ingredient Notification. This will finally allow the Company to inform consumers of the benefits of its cannabinoid products and expand its sales in the United States by opening up mass retail channels. Since passage of the Farm Bill 2018, the FDA has not provided any clear regulation on the CBD market. The lack of a clear, regulated framework has allowed an expanding pool of producers, manufacturers and marketers to flood the market with substandard products and an abundance of questionable advertising tactics. Creating and enforcing industry-wide standards would help create a necessary roadmap for all CBD products and bring organization to an industry that has otherwise been operating without order."

10:41 EST Salesforce's Slack not loading for some users - On its Status webpage, Slack said, "Slack is not loading for some users. We are continuing to investigate the cause and will provide more information as soon as it's available." Reference Link

10:02 EST WPP acquires Village Marketing, terms not disclosed - WPP announces the acquisition of Village Marketing in North America, the industry leader in influencer marketing and creator economy partnerships. The company said, "Founded in 2013 by Vickie Segar, Village Marketing has 150 employees and was specifically created with the vision of building brands in a social media and mobile first world. It was one of the first creative firms to fully honour the unique impact of creators and has led creative campaigns for some of the foremost consumer brands of the last decade, including Equinox, Nike, Netflix, The Farmer's Dog, Boll and Branch, Honest Co., Tommy John, SoulCycle, and many others. Village Marketing will join the Wunderman Thompson network to strengthen its commitment to the creator economy. Given the ubiquity of social media, creators are among the most powerful voices of today. This acquisition will allow Wunderman Thompson to offer its clients and brands much deeper and more direct access to the creator economy." The acquisition is part of WPP's accelerated growth strategy and focused M&A approach to further strengthen its core creative capabilities in marketing, communications and design, and follows the acquisition of Made Thought in December 2021.

10:00 EST Tempur Sealy falls -13.0% - Tempur Sealy is down -13.0%, or -$4.86 to $32.55.

10:00 EST BP Prudhoe Bay rises 8.5% - BP Prudhoe Bay is up 8.5%, or 80c to $10.25.

10:00 EST Meritor rises 44.9% - Meritor is up 44.9%, or $11.06 to $35.73.

09:54 EST BWV Stock trading resumes

09:48 EST Home Depot not forecasting any further inflation, executive says

09:47 EST Mechel falls -10.3% - Mechel is down -10.3%, or -37c to $3.24.

09:47 EST Cian falls -17.9% - Cian is down -17.9%, or -$1.41 to $6.45.

09:47 EST BRC Inc. rises 8.4% - BRC Inc. is up 8.4%, or $1.57 to $20.35.

09:45 EST Vicinity Motor receives order for 100 VMC 1200 EV trucks - Vicinity Motor announced that it has signed a sales and marketing agreement with Paradigm Automotive Corporation, an automotive sales, leasing and upfitting company in Ontario, Canada, including an initial CAD$12.0 million order for 100 VMC 1200 Class 3 electric trucks. Paradigm has also been appointed to act as Vicinity's exclusive dealer in the Hamilton and Niagara regions of Ontario. The VMC 1200 deliveries are expected to begin in the second quarter of 2022.

09:44 EST HireQuest closes Dubin Group, Dubin Workforce Solutions acquisition - HireQuest announced that it has completed the previously disclosed acquisition of The Dubin Group and Dubin Workforce Solutions, related founder-owned businesses in Philadelphia, Pennsylvania that provide executive placement services and commercial staffing, respectively. Simultaneously with the closing of the acquisition, HireQuest, Inc. closed on the sale of Dubin Workforce Solutions to a new franchisee and completed the conversion of the business to its HireQuest Direct model. The Dubin Group was converted to HireQuest's Snelling franchise model and will be sold to a franchisee in the future.

09:42 EST Auddia announces employee inducement grant - Auddia announced that the compensation committee of Auddia's board of directors granted Theo Romeo, the Company's recently-hired VP of Marketing, an inducement stock option to purchase an aggregate of 138,750 shares of Auddia's common stock on February 16, 2022. This stock option was agreed to as an inducement material to Mr. Romeo entering into employment with Auddia. The option was agreed to and granted in accordance with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price of $1.79 per share, which was equal to the closing price of Auddia's common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal annual installments over the next three years, subject to the new employee's continued service with the Company. The stock option has a 10-year term and is subject to the terms and conditions of an inducement stock option agreement covering the grant.

09:41 EST Applied UV enters three year agreement through Airocide Nordic Oy - Applied UV announces that it's Scandinavian distributor Airocide Nordic Oy has entered into a three-year agreement with Plandent Division for distribution of its patented Airocide commercial air purification systems to the professional dental community launching initially in Finland, expanding distribution to include all of the countries in Scandinavia and plans to broaden expansion throughout all of Europe.

09:40 EST Moderna initiates Phase 3 portion of trial for mRNA RSV vaccine candidate - Moderna announced that the Data and Safety Monitoring Board for the RSV program has endorsed the start of the Phase 3 portion of the pivotal clinical study of mRNA-1345, the Company's Respiratory Syncytial Virus vaccine candidate, in adults 60 years and older. The DSMB's endorsement comes after independent review of preliminary Phase 2 data, which suggest that the vaccine has an acceptable safety profile in older adults at the selected dose. This study is known as ConquerRSV. mRNA-1345 is a vaccine against RSV encoding for a prefusion F glycoprotein, which elicits a higher neutralizing antibody response compared to the postfusion state. mRNA-1345 uses the same lipid nanoparticle as Moderna's COVID-19 vaccine and contains optimized protein and codon sequences. The FDA has granted Fast Track designation for mRNA-1345 in adults older than 60 years of age. The primary purpose of the Phase 3 segment of the study is to establish the safety and efficacy of mRNA-1345 vaccine in adults older than 60 years of age in support of licensure. Moderna expects to enroll approximately 34,000 participants

09:38 EST Goodbody Health announces moves up to OTCQB - Goodbody Health is pleased to announce that it has moved up a tier from the over the counter market pink market to the OTCQB market. Goodbody Health welcomes the increased compliance and scrutiny that demonstrates the governance of the group and allows it to be more visible to larger investors

09:35 EST Phio Pharmaceuticals initiates in vivo studies of INTASYL based antivirals - Phio Pharmaceuticals announced the start of efficacy animal studies with INTASYL-based antiviral compounds against SARS-CoV-2 infection, the virus that causes COVID-19. The studies will further investigate the efficacy of Phio's INTASYL technology for treating SARS-CoV-2 infection in a validated mouse model of airway epithelial cell infection, after earlier positive findings in laboratory tests conducted by two independent research facilities. Considering the ongoing pandemic is fueled by new viral variants, the INTASYL-based antiviral compounds are designed to be effective against existing and future variants. Novel drugs designed using the INTASYL technology provide an efficient hit to lead process by bioinformatics-based drug design using a proprietary algorithm. This process requires the design of ~20 compounds for a single target which can then be screened to provide a lead compound for optimization. The INTASYL antiviral compounds being studied to treat SARS-CoV-2 infection are designed against three targets, including two virus-related targets and one novel host-related target. These compounds were tested and activity confirmed in laboratory tests with two different in vitro models of SARS-CoV-2 infection at two independent laboratories. Based on these in vitro data, three compounds, one per target, have been selected for further in vivo testing.

09:31 EST BWV Stock trading halted, volatility trading pause

09:31 EST MGP Ingredients to build new $16.7M extrusion plant - MGP Ingredients announced it will build a technologically advanced extrusion plant to produce its ProTerra line of texturized proteins. The new plant will be located adjacent to the company's existing Atchison, Kansas, plant. Once online in late 2023, the new extrusion plant is expected to produce up to 10M pounds of ProTerra per year.

09:30 EST Texas Capital partners with Huston-Tillotson University - Texas Capital Bancshares has expanded its Commercial Lending Certificate Program to Huston-Tillotson University in Austin, Texas. Texas Capital Bank and ABA began the Commercial Lending Certificate Program for Historically Black Colleges and Universities in 2021 with Prairie View A&M University located in Prairie View, Texas. As an ABA member, Texas Capital Bank is able to extend its member resources to provide specialized certificate programs to collegiate institutions, such as Huston-Tillotson University.

09:29 EST Diana Shipping announces time charter contract for M/V San Francisco - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Koch Shipping Pte. Ltd., Singapore, for one of its Newcastlemax dry bulk vessels, the m/v San Francisco. The gross charter rate is US$30,500 per day, minus a 5% commission paid to third parties, for a period until minimum March 1, 2023 up to maximum May 15, 2023. The charter commenced retroactively as of February 18, 2022. The m/v San Francisco was chartered, as previously announced, to Olam International Limited, Singapore, at a gross charter rate of US$17,750 per day for the first one hundred five days of the charter period and US$24,700 per day for the balance period of the time charter, in each case minus a 5% commission paid to third parties. The "San Francisco" is a 208,006 dwt Newcastlemax dry bulk vessel built in 2017. The employment of "San Francisco" is anticipated to generate approximately US$11.32 million of gross revenue for the minimum scheduled period of the time charter.

09:27 EST Qualigen Therapeutics CEO says 'excited' for what lies ahead - A shareholder letter read, in part, "As we close out the second month of 2022, I am excited for what lies ahead for our company. The last 45 days have helped to realize the well-constructed strategy of Qualigen, and the next several months will continue to bring opportunities that will impact our company significantly. Looking forward, we are confident that our diagnostics business is about to become stronger. The commercial agreement for FastPack with our partner Sekisui Diagnostics, LLC will soon expire and, I'm pleased to announce that Qualigen will begin to benefit from 100% of the revenue generated from those sales. As a result, we expect to see an increase in our revenue and per-unit profit margins from our flagship diagnostics business. We remain grateful to Sekisui for a strong collaboration and partnership over the last several years and are prepared for Qualigen to resume full commercial responsibility as of April 1, 2022. Qualigen will assume all commercial activities and distribution management for its diagnostics unit in the U.S. and international markets. In anticipation of this change, we have been ramping up our diagnostics sales and marketing activities and production capabilities, without significantly impacting our spend. We are ensuring that the resources are firmly in place to facilitate a smooth transition. Once the license expires, we do not expect any interruption to our diagnostics sales and marketing engine as we will continue to leverage established partnerships with our various distributors in both the US and abroad. We will continue to explore potential opportunities within the diagnostics arena to create new revenue streams to add shareholder value. This includes reviewing potential add-on technologies and products for acquisition or licensing that can further strengthen our diagnostics business. The last two years under the shadow of COVID-19 have demonstrated the importance of rapid, accurate and convenient diagnostics testing, areas where Qualigen has excelled over the last 20 years. As a company, we want to be prepared from a technological and operational standpoint for when the next global need arises and to position Qualigen for success in fast-growing market segments. We believe that the focus on keeping Qualigen diversified, that is, continuing to build value from our commercialized medical diagnostics, while seeking to develop new and innovative treatments for rare and Orphan cancers, represents an advantageously differentiated business model. The expected increase in diagnostics revenue and per unit margin will allow us to continue to conduct our business and drive the development of our early-stage cancer therapeutic pipeline assets. Our dual focus on diagnostics and therapeutics drove the decision to acquire exclusive rights to our new lead therapeutic G4-selective transcription inhibitor program, QN-302, from the University College London, a top ten worldwide academic institution, for the potential treatment of pancreatic cancer, and other potential indications. We are particularly pleased to be discussing this recent in-license from UCL for exclusive worldwide rights and the positive news we have already received around it during this time of year. February is Rare Disease Month, and February 28, 2022, Rare Disease Day. Thus, we find it fitting to launch our development efforts of QN-302 for pancreatic cancer during a time designed to raise additional awareness around devastating rare cancers and other rare diseases. Pancreatic cancer is a rare disease. According to the American Cancer Society, each year an estimated 60,430 Americans are diagnosed with pancreatic cancer, with more than 48,220 dying from the disease each year? -- the highest mortality rate of all major cancers. Currently there are few viable treatment options for pancreatic cancer, including surgery, radiation therapy and chemotherapy, which may extend survival or relieve symptoms, but seldom produce a cure. Surgical removal of the tumor is possible in less than 20% of patients diagnosed with pancreatic cancer because detection is often in late stages and has spread beyond the pancreas. Adjuvant treatment with chemotherapy may lower the risk of recurrence. For advanced disease, chemotherapy may lengthen survival. For that reason, we are pleased about the opportunity to develop a potential new approach to treating pancreatic cancer. Professor Stephen Neidle, a globally recognized leader in this space, and his team at the UCL developed a portfolio of small molecules that target regions of cancer genes that have a disproportionately high number of G4s. Preclinical studies show that the investigational QN-302 selectively binds to G4s, forming a complex that may prevent the G4 structures from "unwinding" at the cancer cells' key regulatory regions. In theory, by preventing such "unwinding," QN-302 may inhibit transcription - which has already been seen in preclinical modeling through strong anti-tumor activity in multiple tumor types, including pancreatic cancer animal models - without apparent toxicity at proposed therapeutic doses. Further, preclinical studies suggest encouraging anti-tumor activity against chemotherapy-resistant tumors. We were therefore thrilled to welcome Professor Neidle as a consultant to Qualigen as we prepare to initiate IND-enabling studies for QN-302. As we announced this month, Dr. Neidle will serve to help build scientific understanding regarding data results, including authorship and presentation to the scientific community. As announced last week, we are already off to a strong start with three abstracts accepted to the prestigious American Association for Cancer Research (AACR) conference in April, where Professor Neidle will present regarding QN-302. We look forward to sharing the data from these abstracts at the time of the AACR conference. As we make progress on our lead therapeutic program QN-302, we continue to invest in our QN-247 and RAS-F pipeline programs. We remain cautiously optimistic by the therapeutic potential of these assets as their differentiated mechanisms fit well within our strategy to treat rare Orphan cancers like acute myeloid leukemia. To accomplish this, we are further strengthening our collaboration with the University of Louisville while working to identify cost-saving efficiencies within our third-party vendor networks. Our RAS-F platform will benefit from an operationally streamlined process to identify and advance promising leads for further preclinical development, and from these efforts we anticipate opportunities to present promising new data at future conferences. We are off to a strong start for the year, with exciting new diagnostics opportunities and a clear path forward for our lead therapeutics program. We continue to develop our pipeline in Orphan oncology, including our QN-247 and RAS-F programs, and anticipate multiple reportable milestones throughout the year. As a priority, we will continue to carefully manage our cash in order to both maximize shareholder value and support business opportunities."

09:25 EST Mondelez highlights long-term growth strategy in AMEA region - Mondelez International will today spotlight its strategy for the Asia Pacific, Middle East & Africa region at the 2022 Consumer Analyst Group of New York Conference. Dirk Van de Put, Chairman and Chief Executive Officer, and Maurizio Brusadelli, Executive Vice President & President, AMEA, will detail the attractive growth opportunities in this large and diverse region, as well as key strategic initiatives designed to advance sustainable growth and create shareholder value. Mondelez International offers market-leading brands in key geographies that drive its success in the region. Ninety percent of AMEA revenue comes from focus brands, including two $1 billion global brands in Oreo and Cadbury Dairy Milk, as well as 11 brands with revenues of more than $100 million, including local jewels such as Bournvita and Kinh Do. The company's long history in the region - combined with its local-first strategy, robust supply chain, sophisticated route-to-market infrastructure and high levels of investment - represent key competitive advantages. The AMEA region has delivered robust growth, averaging mid-single digits over the past three years, underpinned by strong volume growth, healthy pricing and continued productivity gains. At the conference, Brusadelli will outline the company's AMEA strategy, providing further detail on its plans to accelerate revenue and share gains in the region by prioritizing: Increasing brand penetration and expanding the portfolio in core snacking categories of chocolate and biscuits; Growing distribution and channel exposure; Entering white spaces and adjacencies; Mondelez International will also showcase its business in India and China - two of the region's fastest-growing markets - to highlight the company's strategy in action.

09:23 EST Intapp enters strategic partnership with Microsoft - Intapp announced a strategic partnership with Microsoft to accelerate the adoption of cloud technologies by private capital, investment banking, legal, accounting, and consulting firms. Through a new multiyear strategic partnership, Intapp will deliver connected firm and deal management solutions on a Microsoft Azure-based industry cloud with deep integrations between Microsoft technologies, including Microsoft 365, and Intapp applications. Under the partnership, Intapp will adopt Azure as its preferred platform for delivering the industry cloud for professional and financial services, helping firms harness the full power of purpose-built software and services that support the modern workplace. Together, Microsoft and Intapp will help partner-led firms unlock the full value of their data, deliver context-aware intelligence to professionals, implement greater operational efficiency, and ultimately, deliver better outcomes for their investors and clients.

09:21 EST Wipro forms joint go-to market partnership with vFunction - Wipro announced that it has formed a joint go-to market partnership with vFunction, a Palo Alto-based startup that has developed a scalable, AI-based technology platform for modernizing Java applications and accelerating migration to the cloud. In conjunction with this partnership, Wipro Ventures, the corporate investment arm of Wipro, announced that it has invested in vFunction's Series A funding round to deepen the strategic partnership.

09:20 EST Newell Brands repurchases $275M of its shares from Icahn Enterprises - Newell Brands announced that on February 21 it entered into an agreement to repurchase approximately $275M of the company's common shares beneficially owned by Carl C. Icahn and certain of his affiliates at a purchase price of $25.86 per share, the closing price of Newell Brands' common shares on February 18 the last trading day prior to the execution of the purchase agreement. Newell Brands will utilize cash on hand and its existing credit facility to fund the share repurchase. The share repurchase is expected to close no later than February 25 subject to customary closing conditions, after which Icahn Enterprises is expected to own approximately 33M common shares of Newell Brands, which represents approximately 8% of the company's outstanding shares. This share repurchase will be made pursuant to the existing authorization under the company's $375M share repurchase program, associated with Newell Brands' planned divestiture of the Connected Home & Security business. At the time of the announcement of this transaction, Newell Brands indicated that it anticipates using the after-tax proceeds toward both debt paydown and share repurchase, with the goal of maintaining the company's current leverage ratio. The company continues to expect this divestiture to be completed by the end of the first quarter of 2022, subject to customary closing conditions, including regulatory approval. Ravi Saligram, Newell Brands President and CEO, said, "Today's announcement of the share buyback reflects our confidence in the strategy we have been implementing, which is yielding strong results, and is expected to create tremendous shareholder value. We are thankful to Carl Icahn, Brett Icahn and their Board representatives for their support and guidance over the past several years and look forward to their continued contributions going forward." Carl Icahn said, "I remain an avid supporter and believer in Newell Brands' management team and their strategy, which has strengthened the company's underlying performance and reignited their top line momentum. I look forward to our continued partnership, as I remain one of the company's largest shareholders, with approximately 33M shares valued at $855M."

09:19 EST AvePoint enhances global partner program - AvePoint revealed enhancements to its global partner program, which is designed to equip partners including managed service providers, value added resellers (VARs), cloud consultants and DevOps partners, with the right technology and tools to capitalize on collaboration security revenue opportunities. It also aligns benefits and resources to various partner business models and technology delivery preferences, and has been serving partners since its official launch in July 2021. By the end of 2021, AvePoint had over 2,800 total partners, of which, over three quarters were active MSPs. In addition, as reported in 3Q earnings, AvePoint experienced triple-digit growth in monthly recurring revenue from the AvePoint Elements Managed Services Platform.

09:18 EST Home Depot sees 2022 operating margin flat to 2021

09:16 EST Kraft Heinz updates long-term growth targets ahead of CAGNY conference - Kraft Heinz will discuss progress the company is making against its strategic transformation plan at the 2022 Consumer Analyst Group of New York, or CAGNY, Conference. Taking into account the reorientation of the business to date and confidence in its next phase, Kraft Heinz will also announce that it is increasing its long-term growth targets, including: organic net sales growth from 1%-2% to 2%-3%; adjusted EBITDA growth from 2%-3% to 4%-6%; adjusted EPS growth from 4%-6% to 6%-8% with greater than or equal to 100% free cash flow conversion.

09:13 EST Progenity shares poster presentations on treatment of gastrointestinal disorders - Progenity shared two poster presentations that were presented during the 17th Congress of the European Crohn's and Colitis Organisation on February 18, 2022. Dr. Geert D'Haens and Mr. Joep van Oostrom shared a poster titled "Pharmacokinetic stratification of cytokine profiles during anti-TNF induction treatment in moderate-to-severe UC," which explores potential causes for the 30% of patients who are primary non-responders to anti-TNF therapies. The pro-inflammatory cytokine interleukin 6 was observed at high levels in tissue, suggesting it may be a driver of inflammation alternative to TNF in ulcerative colitis. This suggests a need for combination therapy. Dr. Bram Verstockt and Dr. Severine Vermeire presented a poster titled "Tofacitinib tissue exposure correlates with endoscopic outcome," which highlighted a significant relationship between mucosal exposure and endoscopic improvement in tofacitinib-treated patients with moderate to severe ulcerative colitis.

09:11 EST CarGurus rolls out Instant Max Cash Offer to California - CarGurus has launched its fully-digital car selling solution, CarGurus Instant Max Cash Offer, on the West Coast. Now, California residents can take advantage of the company's revolutionary platform that brings wholesale and retail together to deliver consumers the best selection of inventory, the maximum offer to buy their vehicle from in-network dealers, and the ultra-convenience of white-glove pick up service.

09:09 EST Matthews enters joint development agreement with Illuming Power - Matthews International Corporation announced a Joint Development Agreement with Illuming Power Inc., a Vancouver BC engineering firm specializing in the design, prototype, manufacture and sale of hydrogen fuel cell related materials, components and stacks. This two-year partnership will develop an automated, expanded graphite bipolar plate production line that will dramatically reduce production costs, accelerating the mass market adoption of fuel cells for a variety of end-use markets, including for transportation and stationary applications.The JDA builds on the established global position Matthews holds in production lines for the clean energy market, where the Company is a leader in calendaring lines for electrode production of lithium-ion batteries for the electric vehicle market, and on its growing expertise in fuels cells following the acquisition of Terrella Energy Systems in May 2021.

09:08 EST U.S. Bancorp partners with Microsoft on banking with cloud computing - U.S. Bank (USB) announced a substantial investment in modernizing its technology foundation through the selection of Microsoft (MSFT) Azure as its primary cloud provider for U.S. Bank applications. U.S. Bank and Microsoft will work to develop new growth opportunities that will allow U.S. Bank to expand its partnerships and take advantage of an ever-evolving financial services marketplace.

09:07 EST LMC, CPP Investments form $979M multifamily joint venture - Canada Pension Plan Investment Board and LMC, a wholly-owned subsidiary of Lennar, have formed a new joint venture to develop Class-A multifamily residential communities across high-growth metropolitan areas in the U.S. CPP Investments and LMC have allocated $979M in equity to the joint venture. CPP Investments will own a 96% stake and LMC will own the remaining 4%.

09:06 EST Home Depot has grown business by over $40B over two years, CEO says - Comments taken from Q4 earnings conference call.

09:05 EST AgriFORCE Growing Systems enter licensing agreement with Radical Clean Solutions - AgriFORCE Growing Systems has entered into an exclusive worldwide licensing agreement with Radical Clean Solutions, to commercialize their new proprietary hydroxyl generating devices within the controlled environment agriculture and food manufacturing industries. The patent pending system seeks out and destroys both airborne and surface-based mold, bacteria, virus, odorous and volatile organic compounds, as well as other pathogens and pollutants in real-time. The license grants the rights to AgriFORCE in perpetuity as well as joint patent ownership rights for CEA.

09:04 EST Medtronic says FY23 will be a 'unique and challenging year' - Does not expect EPS growth above revenue growth in FY23. Says committed to long range plans. Says dialogue with FDA "ongoing and constructive." Says seeing wage inflation of about 9%.

09:04 EST Rubicon announces multi-year agreement with SRS Distribution - Rubicon Technologies announced that it has entered into a multi-year agreement with SRS Distribution. Rubicon will bring its suite of cloud-based software products, and the power and scope of its network of more than 7,000 hauler and vendor partners, to bear in providing scalable waste, recycling, and sustainability solutions to SRS in support of the company's environmental and business goals.

09:01 EST BTCS appoints Manish Paranjape as CTO - BTCS Inc. announced the appointment of Manish Paranjape as Chief Technology Officer. Paranjape, who has been working as a consultant for BTCS since the first quarter of 2021, brings more than 25 years in the technology sector to his CTO role at BTCS. Previously, Paranjape was VP of Technology and Research at Corra, a leading digital commerce agency. Prior to joining Corra, Paranjape was CTO of REGARD, where he was integral to the development of GoGoin, a global digital currency payment gateway for e-commerce merchants.

08:59 EST Trust Stamp appoints Reuben Farrugia as Malta Research Director - Trust Stamp welcomes Prof. Reuben Farrugia to its team as Malta Research Director amidst ongoing investment in research and development alongside multiple patent filings in early 2022. As an internationally recognized authority in biometrics with nearly two decades of experience in image processing and computer vision and over 70 international peer-reviewed publications, Prof. Farrugia brings deep expertise to the Trust Stamp team. He maintains active industry leadership as an Associate Professor at the University of Malta, National Contact for the European Association of Biometrics, and IIEE Senior Member, having previously served as General Chair to the IEEE International Workshop on Biometrics and Forensics.

08:57 EST iPower acquires Anivia Limited for $12M - On February 15, 2022, iPower acquired Anivia Limited, a British Virgin Islands company, for $12 million. Anivia Limited controls a 100% interest in iPower's largest global co-engineering partner, Daheshou Shenzhen Information Technology Co. DHS is a service provider based in Shenzhen, China that is engaged in R&D, distribution, quality assurance, end-to-end supply chain management services, and online merchandising services. DHS provides these services to markets throughout North America, Europe and Asia. DHS generated approximately $9.0 million of gross sales in fiscal year 2021, with the majority of that revenue coming from iPower, DHS's largest customer. The acquisition of DHS will expand iPower's current supply chain and e-commerce capabilities through in-house product sourcing, manufacturing network management, quality assurance processes and R&D expertise. The $12.0 million in transaction consideration includes $1.5 million of cash and a $3.5 million unsecured promissory note, with the remaining $7.0 million paid in the form of 3,083,700 shares of iPower common stock, valued at $2.27 per share, which was the closing price of our common stock traded on the Nasdaq Capital Market on February 15, 2022. The promissory note bears interest at a rate of 6% per year and will mature in two years. All common stock issued is subject to a 180-day lock-up period following the closing of the transaction.

08:56 EST United Fire Group CEO Randy Ramlo to retire - United Fire Group President and Chief Executive Officer Randy Ramlo announced he will retire from the company in 2022. A long-term UFG employee, Mr. Ramlo has served in his current role since May 2007. Mr. Ramlo will continue in his current role until a successor is named and intends to remain in a consulting role to the company during the transition process following the appointment of a new CEO. Mr. Ramlo's anticipated retirement date from UFG is October 31, 2022, pending the successful completion of an executive search process for his successor.

08:54 EST Small Pharma announces analysis of Phase I data from SPL026 trial - Small Pharma is pleased to share the analysis of Phase I data from the combined Phase I/IIa clinical trial of SPL026 with psychotherapy for the treatment of Major Depressive Disorder. In the dose-escalating, placebo-controlled Phase I study, 32 healthy psychedelic naive volunteers across four dose cohorts received either SPL026 in combination with psychotherapy or placebo. This analysis provides additional insight into dose-related effects on the primary outcomes of safety and tolerability as well as on pharmacodynamic measures, including the treatment experience and subject well-being. Key results: No drug-related serious adverse events and minimal short-lived adverse events reported on dosing day. Of 20 drug-related adverse events, all were mild or moderate and resolved rapidly and independently. No statistically significant negative effects on anxiety and well-being identified at any point during the three-month follow-up. Data show a clear correlation between quality of psychedelic experience and dosing levels, starting at 9mg and up to 21.5mg, across all four cohorts. Participant-reported scores, using a 0 to 100 scale, on the richness of the psychedelic experience demonstrated increasing values of 48, 79, 79, 88 across the four increasing doses. A dose correlation was seen across most patient-reported scores. Therapist assessment of the predicted therapeutic benefit of SPL026 demonstrated a positive relationship with dose. In the majority of participants, there was a strong correlation between levels of N,N-dimethyltryptamine in the body and the quality and intensity of the psychedelic experience. IV administration of SPL026 offers a short-lived, well-tolerated psychedelic experience of ~20 minutes, enabling a dosing session to last only ~30 minutes. Pharmacokinetic sampling supported rapid clearance out of the body, showing near undetectable DMT levels in the blood by 60 minutes at all investigated doses. The data confirms the selected dose of SPL026 taken forward into Phase IIa most consistently delivers the target treatment profile across subjects through a multi-dimensional assessment including safety, tolerability, pharmacokinetic and pharmacodynamic parameters. The full dataset is anticipated to be published in a peer reviewed journal. The blinded, randomized, placebo-controlled, proof-of-concept Phase IIa study of SPL026 in combination with psychotherapy in 42 patients with MDD remains on track to deliver topline results in the first half of 2022. This study will assess the efficacy of one dose of SPL026 versus a placebo, and one versus two doses of SPL026 in combination with psychotherapy in patients with MDD while bolstering existing safety and tolerability data.

08:50 EST Nuvectis Pharma announces data for NXP900 in preclinical models - Nuvectis Pharma announced a publication in Cancer Research by scientists from the University of Edinburgh titled Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors, highlighting NXP900's robust activity in preclinical models of Triple Negative Breast Cancer with Integrin-Linked Kinase loss. NXP900 is Nuvectis' novel and highly-selective SRC/YES1 inhibitor that effectively shuts down SRC-mediated signaling by inhibiting both the catalytic and scaffolding functions of SRC/YES1 kinases, without triggering immunosuppressive effects. The study was led by Dr. Valerie G. Brunton, Ph.D., Professor and Chair of Cancer Therapeutics at the Institute of Genetics and Cancer at the Cancer Research UK Edinburgh Centre in Edinburgh, Scotland. Dr. Brunton and the team at the University of Edinburgh demonstrated that loss of ILK sensitizes TNBC to treatment with SRC inhibitors, and that treatment with NXP900 was superior to treatment with bosutinib, an approved multi-kinase inhibitor that is known to inhibit the catalytic function of SRC kinase. Importantly, it was shown that NXP900 completely blocked the growth of ILK-knock-out tumors demonstrating superiority vs bosutinib. The studies also showed that NXP900 was significantly more potent in the same TNBC model versus bosutinib. This further supports the notion that complete shutdown of SRC-mediated signaling is key to unlocking the full potential of SRC inhibition as an anti-cancer treatment strategy.

08:49 EST Marriott Vacations increases share repurchase authorization by $300M - Marriott Vacaciones increased its prior authorization to repurchase common stock of the company by $300M. As of February 17, the company had approximately $145M of capacity remaining under its prior authorization, and the increase in authorization provides a total remaining capacity of approximately $445M.

08:48 EST Troika Media says Super Bowl LVI 'milestone moment' for the company - Troika Media Group announced that last week's Super Bowl LVI was a milestone moment for the company, as Troika has been creative partners with the Los Angeles Rams, SoFi, and the Los Angeles Super Bowl Host Committee on a slate of branding, marketing and fan experience initiatives, including engineering the Rams game day experience on the massive 360-degree, two-sided Infinity screen. In partnership with the Los Angeles Sports & Entertainment Commission, Troika created the logo, identity, and the launch campaign for the Los Angeles Super Bowl Host Committee to welcome the massive event back to LA. They kicked it off with a :90-second film featuring Snoop Dogg, declaring LA not only the home of this year's Super Bowl, but the preeminent home of the NFL. The spot leaned heavily into iconic Los Angeles footage and the future-forward ideals of one of the world's most diverse cities. For the LA Rams, the ask for the in-stadium experience was a big one: Turn every Los Angeles Rams moment into an expressive brand experience and delight Angelinos with memorable and high-impact moments throughout the game. The entire presentation was designed to engage and excite fans, while embracing, celebrating and capturing the spirit of the city. For SoFi the primary goal of the engagement was to raise brand awareness through NFL gamedays. They needed to introduce the brand and their unique offerings to fans and do it in creative ways that enhance, rather than detract from, their game experience. Troika seized this opportunity to create a fan-centric, experience that owned key moments for the SoFi Brand. Troika continues to work with the LA Rams and SoFi stadium for the upcoming 2022-23 season, along with other world-class sports and entertainment brands to be announced throughout the year.

08:46 EST PFSweb announces second fulfillment center in Las Vegas area - PFS is opening a second fulfillment center in North Las Vegas, NV, in close proximity to its existing facility in the Las Vegas area. With this new facility, PFS' North American fulfillment center footprint has now expanded to eight facilities. PFS also operates two fulfillment centers in Europe. Following the announcement of its first facility opening in the Las Vegas area in 2021, PFS received strong interest from existing clients to quickly add a western node to their fulfillment operations. As a result, this fulfillment center reached capacity just before the holiday peak season and is comprised of ten unique branded fulfillment operations. The new fulfillment center is scheduled to open in Q2 2022 and is estimated to bring up to 300 full-time, part-time, and seasonal jobs to the local market by the end of 2022. PFS plans to use the additional capacity for new client opportunities as well as to further enable growth opportunities with existing clients via a multi-node fulfillment strategy. There are also plans to add contact center training environments within the building to provide in-person training for new employees.

08:44 EST XpresSpa opens second COVID-19 testing facility at Denver International Airport - XpresSpa announced that it has opened a second XpresCheck COVID-19 testing facility at Denver International Airport. XpresCheck is located pre-security in the Great Hall with six separate testing rooms. COVID-19 testing options include a Rapid RT-PCR test and the standard Polymerase Chain Reaction Test.

08:43 EST Eli Lilly signs long-term lease with Alexandria Real Estate for new institute - Alexandria Real Estate (ARE) announced that Eli Lilly (LLY) has signed a 334,000 RSF long-term lease for the development of Lilly's new Institute for Genetic Medicine in the Seaport life science submarket of Greater Boston. 15 Necco is a sustainable office/laboratory development that offers a waterfront presence and views of Boston. The building, which is targeting LEED Gold Core & Shell, Fitwel, WELL and WiredScore Platinum certifications, commenced construction in 2021 and is expected to deliver in late 2023. Lilly has also leased 36,000 RSF at 215 First Street, owned and operated by Alexandria, to support the scale-up of its new Institute for Genetic Medicine ahead of anticipated occupancy at 15 Necco in 2024.

08:41 EST DZS appoints Andrew Finkelstein as SVP, North America Sales - DZS announced the appointment of Andrew Finkelstein as Senior Vice President, North America Sales. Mr. Finkelstein joins DZS from Casa Systems, bringing two decades of fixed and mobile access networking experience to DZS as well as long-term customer and channel partner relationships across the region.

08:40 EST Macy's sees 2022 as transitional year

08:39 EST Macy's targeting digital penetration in low to mid 40s% by 2024 - Targeting $10B in digital sales by 2023. Targeting a gross margin rate in the high-30s. Targeting credit card revenues as a percent of net sales slightly lower than historical average of 3% in the near-term before improving to about 3% of net sales by 2024. Expects capital expenditures of approximately $3B over the three years. Targeting to generate between $3.2B-$3.6B of free cash flow over the next three years.

08:39 EST Veracyte appoints Jonathan Wygant as chief accounting officer - Veracyte announced that it has appointed Jonathan Wygant as chief accounting officer, effective immediately. Mr. Wygant will oversee all aspects of the company's global accounting operations, financial reporting and tax functions. He will report to Rebecca Chambers, Veracyte's chief financial officer.

08:38 EST Macy's considered third-party investment, special equity offering, CEO says - CEO Jeff Gennette says that ultimately, the "execution risk" of a spinoff would be too high.

08:37 EST Enlivex Therapeutics appoints Einat Galamidi as VP, medical - Enlivex Therapeutics announced that Einat Galamidi, M.D. has joined its executive management team as Vice President, Medical. Dr. Galamidi joins Enlivex after 10 years at Gamida Cell, where she most recently served as Vice President of Clinical Development.

08:36 EST Macy's: Macro environment will continue to offer some challenges

08:35 EST Ballard Power signs MOU with Adani for hydrogen fuel cells in India - Ballard Power Systems announced it has signed a non-binding Memorandum of Understanding with the Adani Group to evaluate a joint investment case for the commercialization of fuel cells in various mobility and industrial applications in India. Under the MOU, both parties will examine various options to cooperate, including potential collaboration for fuel cell manufacturing in India.

08:34 EST Radiant Logistics announces renewal of share repurchase program - Radiant Logistics announced that its board of directors has authorized the repurchase of up to 5M shares of the company's common stock through December 31, 2023. As of February 1, 2022, the company had 49,443,305 shares outstanding.

08:33 EST Shyft Group board authorizes $250M share repurchase program - The Shyft Group announced that its Board of Directors authorized the repurchase of up to $250 million of its common stock.

08:31 EST Magnite launches Live Stream Acceleration - Magnite announced the launch of Live Stream Acceleration, a technology designed to help CTV publishers optimize their live inventory programmatically. LSA helps publishers more effectively monetize their supply, ensuring that ads are served in a timely manner without burdening their technical infrastructure. By leveraging LSA for live sports over a five week period, Sling TV saw a 47% lift in ad conversions compared to the previous five weeks. Efficiencies via LSA implementation allowed for ad delivery which otherwise would have been lost - which is equivalent to 51 seconds of advertising air time on a standard 1 hour live event. This helps make it easier than ever for advertisers to access premium and scalable inventory on Sling to reach the audiences they want, without technical limitations.

08:30 EST Panbela Therapeutics Inc trading resumes

08:28 EST Splash Beverage Group receives Walmart authorization for TapouT in Arkansas - Splash Beverage Group announced that through its existing distribution agreement with Central Distribution in Arkansas, TapouT, its high-performance energy drink will now be distributed through Walmart in Arkansas. Central Distribution, an Arkansas family-owned wholesale beverage distributor since 1935, will launch all three flavors of TapouT in 125 Walmart stores throughout Arkansas. The agreement will begin with the initial launch in Bentonville, home to Walmart's Corporate Headquarters. Tapout will be featured in all Walmart banners in Arkansas including SuperCenters and Walmart Neighborhood Marts.

08:27 EST Medtronic says markets, customers on path to recovery - Says looking at portfolio with "more critical eye." Says winning share in high and low power devices. Says converting earnings into strong free cash flow is a priority. Targeting full year conversion of 80% or greater. Says increasing R&D investments "broadly across company." Says will continue "opportunistic" share repurchases. Says "several exciting growth catalysts" in the pipeline. Comments taken from Q3 earnings conference call.

08:26 EST Hour Loop expands operations with Taiwan offices - Hour Loop announced it has expanded its operations with the opening of three new offices in Taipei, Taichung, and Tainan. These new offices are part of Hour Loop's expansion plans to broaden its operational capabilities across geographies. Hour Loop recently announced the closing of its $6.9 million initial public offering that occurred on January 6, 2022. The Company is using the proceeds from its listing to repay outstanding debt, purchase inventory, and expand its labor force.

08:25 EST Immix Biopharma initiates GMP manufacturing of IMX-120 - Immix Biopharma announced that it has initiated Good Manufacturing Practice manufacturing of IMX-120, a biologic for inflammatory bowel disease. ImmixBio anticipates filing an IND for IMX-120 in 2023, representing a significant milestone on ImmixBio's path to clinical trials for IMX-120 in inflammatory bowel disease. The IBD market is expected to reach $21.4 billion by 2024 from the existing $18.4 billion in 2019. IMX-120 is a Tissue-Specific Biologic built on ImmixBio's Immune Normalization Technology for IBD with proprietary GLUT1 antibody and other proprietary targeting coupled with polyphenol poly-kinase inhibitors. IMX-120 takes advantage of the fact that overexpression and activation of GLUT1 on overactive immune cells has been shown to be widely present in patients with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. IMX-120 is the latest drug candidate to initiate GMP manufacturing produced by ImmixBio's SMARxT Tissue-Specific Platform.

08:24 EST Applied UV in pact through Scandinavian associate for Airocide distribution - Applied UV announces that it's Scandinavian distributor Airocide Nordic Oy has entered into a three-year agreement with Plandent Division for distribution of its patented Airocide commercial air purification systems to the professional dental community launching initially in Finland, expanding distribution to include all of the countries in Scandinavia and plans to broaden expansion throughout all of Europe.

08:22 EST Panbela Therapeutics to acquire Cancer Prevention Pharmaceuticals - Panbela Therapeutics announced it has entered into a definitive agreement to acquire Cancer Prevention Pharmaceuticals, a private clinical stage company developing therapeutics to reduce the risk and recurrence of cancer and rare diseases, for a combination of stock and future milestone payments. The combined entity will have an expanded pipeline addressing an estimated aggregate $5 billion market opportunity for the areas of initial focus: familial adenomatous polyposis, first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention and ovarian cancer. The combined development programs boast a steady cadence of catalysts with programs ranging from pre-clinical to registration studies, including CPP's lead asset with a fully funded registration trial scheduled to begin this year. In addition, the transaction facilitates operational and commercial synergies, under the leadership of a highly experienced management team with a proven history of drug discovery, development, and commercialization expertise. "This transaction is an important step towards our goal of creating a diversified pipeline with an ability to hit multiple targets and thereby expanding the potential of the combined company," said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. "The combined platforms will be better positioned to treat more patients. This transaction is a tremendous strategic fit and we feel creates robust stockholder value." CPP is developing therapeutics designed to reduce the risk of cancer and other diseases. In addition to the fully funded FAP registration trial scheduled to begin by year-end, a phase 3 trial in colon cancer survivors is currently underway and is sponsored by the Southwest Oncology Group. Additionally, clinical trials in neuroblastoma, gastric cancer, and early-onset type-1 diabetes are underway in collaboration with various nonprofit groups.Under the terms of the agreement and plan of merger, the holders of CPP's outstanding capital stock immediately prior to the merger will receive shares of common stock of Panbela upon closing of the mergers. On a pro forma and fully diluted basis, holders of Panbela common stock are expected to own approximately 59% of the post-merger holding company and holders of CPP securities, including converted indebtedness, are expected to beneficially own approximately 41% of post-merger holding company. CPP stockholders will be eligible to receive contingent payments totaling a maximum of $60 million from milestone and royalty payments associated with the potential approval and commercialization of the lead asset. The proposed mergers have been unanimously approved by the boards of directors of each company and the stockholders of CPP. A closing is expected to occur by the second quarter of 2022, subject to approval of the issuance of securities in the transactions by Panbela's stockholders, and satisfaction of other customary closing conditions. The combined company will be led by Jennifer Simpson, Chief Executive Officer of Panbela and will remain headquartered in Waconia, Minnesota. The board of the combined company is expected to optimize the value of this transaction and beyond and will include at least two members initially designated by CPP, CPP Chief Executive Officer, Jeff Jacob, and CPP Director, Dan Donovan.

08:19 EST Clever Leaves expands partnership with Cansativa - Clever Leaves Holdings announced the expansion of its partnership with German cannabis distributor and wholesaler Cansativa. At the same time, Cansativa announced a Series B fundraise, enhancing Cansativa's ability to grow, capitalize on the existing medical cannabis market and prepare for entry to the potential German recreational market. Casa Verde Capital has agreed to lead an investment round into Cansativa of up to $15 million, followed by other additional investors. This financing round will assist Cansativa in capitalizing on its strong position in the German cannabis market, as well as preparing for the potential German recreational market. In connection with Cansativa's Series B capital raise, Clever Leaves' indirect, wholly owned subsidiary, Clever Leaves Portugal Unipessoal and Cansativa entered a three-year commercial supply agreement. Subject to its terms and conditions, the supply agreement provides that Cansativa will purchase a minimum of EUR2 million of high-THC cannabis flower from Clever Leaves Portugal' Portuguese facilities. Throughout 2022, Clever Leaves will continue to develop its relationship with Cansativa and the German cannabis market by providing safe, reliable, pharmaceutical-grade products through Cansativa's distribution network, which includes thousands of authorized German pharmacies. The supply agreement is expected to be initiated around the end of 2022, contingent upon Clever Leaves Portugal receiving EU GMP certification as well as the closing of Cansativa's fundraise and other conditions. In connection with Cansativa's Series B capital raise, Clever Leaves' indirect, wholly owned subsidiary will sell a portion of its Cansativa holdings, which is expected to generate approximately EUR2.3 million of pre-tax proceeds and reduce Clever Leaves' expected ownership to approximately 9%.

08:18 EST Norwegian Cruise Line announces closing of $2B of notes - NCL Corporation announced that it has closed its previously announced private offerings of $1,000.0 million aggregate principal amount of its 5.875% senior secured notes due 2027, $600.0 million aggregate principal amount of its 7.750% senior unsecured notes due 2029 and $435.0 million aggregate principal amount of its 2.50% exchangeable senior notes due 2027. The offering of the Notes closed on February 18, 2022 and the offering of the Exchangeable Notes closed on February 15, 2022. NCLC used the net proceeds from the offerings of the Notes and the Exchangeable Notes to redeem all of the outstanding 12.25% Senior Secured Notes due 2024 and 10.250% Senior Secured Notes due 2026 and intends to use the remainder of such proceeds to make principal payments on debt maturing in the short-term, including, in each case, to pay any accrued and unpaid interest thereon, as well as related premiums, fees and expenses. The Secured Notes and the related guarantees will be secured by first-priority interests in, among other things and subject to certain agreed security principles, three of our vessels. The Secured Notes are guaranteed by our subsidiaries that own the vessels that will secure the Secured Notes. NCLC has granted the initial purchasers of the Exchangeable Notes an option to purchase, during a 13-day period beginning on, and including, the first day on which the Exchangeable Notes are issued, up to an additional $65.0 million aggregate principal amount of Exchangeable Notes. The Exchangeable Notes are general senior unsecured obligations of NCLC and guaranteed by NCLH. Holders may exchange all or a portion of the Exchangeable Notes at the holder's option at any time prior to the close of business on the business day immediately preceding August 15, 2026, subject to the satisfaction of certain conditions and during certain periods, and on or after August 15, 2026 until the close of business on the business day immediately preceding the maturity date, regardless of whether such conditions have been met. Upon exchange of the Exchangeable Notes, NCLC will satisfy its exchange obligation by paying and/or delivering, as the case may be, cash, ordinary shares of NCLH or a combination of cash and ordinary shares, at NCLC's election. NCLC will pay any cash required to be paid upon exchange of the Exchangeable Notes. If NCLC elects to satisfy its exchange obligation solely in ordinary shares or in a combination of ordinary shares and cash, the Exchangeable Notes will convert into Series A Preference Shares of NCLC, which shall immediately and automatically be exchanged for a number of ordinary shares. The initial exchange rate per $1,000 principal amount of Exchangeable Notes is 28.9765 ordinary shares, which is equivalent to an initial exchange price of approximately $34.51 per ordinary share, subject to adjustment in certain circumstances. The initial exchange price represents a premium of approximately 52.50% above the last reported sale price of the ordinary shares on the New York Stock Exchange on February 10, 2022.

08:17 EST Capstone Green Energy awarded follow-on C1000S order - Capstone Green Energy announced that its southern U.S. Distributor, Lone Star Power Solutions has contracted with a remote data center in Louisiana to provide a five-year rental of a Capstone C1000S microturbine system. This system is the second C1000S to be commissioned at this remote data center, with the first system having been commissioned back in October 2021.

08:16 EST Bandwidth appoints Anthony Bartolo as COO - Bandwidth announced that Anthony Bartolo will be joining the company in the newly created position of Chief Operating Officer, effective Feb. 28. Bartolo has 30 years in companies such as Avaya, Tata Communications and Nortel. Most recently, Bartolo was Executive VP and Chief Product Officer at Avaya. Earlier experience includes President and CEO of Skyrider, a social and peer-to-peer networking start-up, and Vice President and General Manager of the Wireless and RFID Divisions at Symbol Technologies acquired by Motorola.

08:16 EST Exxon Mobil and Papua New Guinea sign P'nyang gas agreement - ExxonMobil subsidiary Esso PNG P'nyang Limited, Ampolex Limited, and the Independent State of Papua New Guinea have signed the P'nyang project gas agreement for the proposed development of the P'nyang LNG project. Subject to a final investment decision by the P'nyang project co-venturers, the ExxonMobil-operated P'nyang project would deliver LNG by constructing new upstream facilities in Western Province linked to existing infrastructure. The agreement provides the fiscal framework for the project and supports project scoping and evaluation. The P'nyang field is estimated to have 4.36T cubic feet of gas. "On behalf of ExxonMobil and the other co-venturers, I thank the PNG national government along with the government of Western Province for their partnership in moving the P'nyang project forward," said Liam Mallon, president, ExxonMobil Upstream Oil and Gas. "The P'nyang project gas agreement marks a significant milestone and underscores the intent of all stakeholders to set a clear framework toward the P'nyang project's future development." The P'nyang development in Western Province is proposed to commence following the Papua LNG project, which will be located in Gulf Province. The phased approach to gas development would support ongoing economic growth in Papua New Guinea. The P'nyang project will be an independent project with landowner benefits to be provided under a future benefit sharing agreement to be negotiated by the State in accordance with the Oil and Gas Act.

08:15 EST Kiniksa sees 2022 ARCALYST net revenue $115M-$130M - Kiniksa expects ARCALYST net revenue for the full-year 2022 to be between $115 million and $130 million.

08:13 EST Actinium Pharmaceuticals and Aveo Oncology to co-develop radiotherapy - Actinium Pharmaceuticals (ATNM) and Aveo Oncology (AVEO) have entered into a research collaboration to develop and study a first-in-class antibody radio-conjugate targeting ErbB3, also known as HER3. Actinium will utilize its AWE technology platform and extensive radiotherapy know-how to conjugate one of AVEO's ErbB3 targeted antibodies, with the potent alpha-emitting radioisotope Actinium-225. Actinium's AWE technology platform has created a Ac-225 CD38 targeting ARC using the blockbuster myeloma antibody daratumumab, in collaboration with EpicentRx for targeted radiotherapy CD47-SIRPalpha immunotherapy combinations and in collaboration with Astellas Pharma, to create theranostics for solid tumors. Actinium employs a multidisciplinary approach leveraging its team's expertise and experience in cancer cell biology, radiochemistry, radiation sciences, immunology and oncology drug development to R&D and collaborations. AVEO's ErbB3 targeting antibodies are designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers and has demonstrated preclinical activity in multiple tumor models.

08:12 EST Humana to add two new independent directors in Starboard cooperation agreement - Humana announced a board refreshment plan under which the company will add two new independent directors to its board of directors as part of a cooperation agreement with Starboard. As part of the refreshment plan, the Humana board will appoint two new independent directors mutually agreed upon by the company and Starboard, the first before Humana's 2022 annual meeting of shareholders and the second following. In keeping with Humana's active board refreshment process, one incumbent director will not stand for re-election at the 2022 annual meeting and a second incumbent director will not stand for re-election at the 2023 annual meeting.

08:12 EST Morphic presents MORF-057 data at ECCO 2022 - Morphic Therapeutic announced the Digital Oral Presentation of new data at the 17th Congress of European Crohn's and Colitis Organisation supporting the ongoing MORF-057 development program in inflammatory bowel disease. The data presented at ECCO characterized alpha4beta7 expression of immune cells at single-cell resolution in blood and assessed the dose-dependent effect of MORF-057 administration in nonhuman primates. These studies recapitulated results from human clinical data including a clear dose-response accompanied with changes in circulating gut-homing T-memory cells and CCR9 transcripts corresponding with complete alpha4beta7 receptor occupancy.

08:11 EST Bally's special committee retains advisors for Standard General proposal - Bally's The special committee of independent and disinterested directors, formed to evaluate the preliminary, non-binding acquisition proposal from Standard General, has retained Macquarie Capital as its financial advisor and Potter Anderson & Corroon as its legal counsel in connection with its evaluation of the Proposal, as well as any potential strategic alternatives to the Proposal. No decisions have been made with respect to the Proposal. There can be no assurance that any definitive offer will be made or accepted, that any agreement will be executed or that any transaction will be consummated.

08:10 EST Poet advances toward Nasdaq listing with 10-for-1 share consolidation - POET Technologies announced as the key next step in its Nasdaq listing process that it has determined to proceed with a ten-for-one consolidation of its common shares in order to meet Nasdaq listing requirements and the Company's own post-consolidation price target. The Company expects that trading of the Common Shares on a post-consolidation basis on the TSX Venture Exchange will commence on or about Monday, February 28, 2022. The Company's name and trading symbol on the TSXV will remain unchanged. The Consolidation was previously approved by the Board on the recommendation of its Subcommittee, as well as by shareholders at the recent annual general and special meeting of shareholders of the Company. The Board believes the Consolidation will result in a number of potential benefits to POET, including meeting the minimum bid price requirement for the Nasdaq listing and achieving a post-Consolidation share price target that will support attracting a broader institutional investor base for the Company. The Company has been notified that an approval letter from the Nasdaq will be issued following a minimum 5 days of trading of its post-consolidated shares on the TSXV. The Company's common shares are expected to begin trading on the Nasdaq approximately 7 - 10 days following consolidation, but the timing cannot be assured. Once final, the Company's shares will trade on the Nasdaq Capital Market under the symbol "POET".

08:09 EST Macy's 'stronger, more agile' than before pandemic, says CEO Gennette - Comments taken from Q4 earnings conference call.

08:08 EST CVS Pharmacy launches six new innovative home health care products - CVS Pharmacy, the retail division of CVS Health, announced the launch of six new innovative home health care products as an extension of the company's exclusive CVS Health product line. Rooted in customer insights and specifically designed to meet the needs of the aging, caregivers and those living with disabilities, these bathroom safety and mobility products merge function and design. The products were developed in collaboration with Michael Graves Design, pioneers of the Design for All movement, which leverages the power of design to improve people's everyday lives. The new CVS Health by Michael Graves Design assortment features a variety of products ranging from comfort grip canes and easy-fold travel walkers to convertible shower chairs and 3-in-1 comfort commodes. Most products are now available on CVS.com and hitting shelves through March at more than 6,000 CVS Pharmacy retail locations nationwide.

08:08 EST RenovoRx enrolls1st pancreatic cancer patient in TIGeR-PaC trial at Columbia - RenovoRx announced enrollment of its first patient at one of its newest clinical sites, Columbia University New York-Presbyterian Hospital Irving Medical Center , in its ongoing TIGeR-PaC Phase 3 clinical trial. The study is evaluating the Company's therapy platform RenovoTAMP , as a potential treatment option for locally advanced pancreatic cancer that may extend life while improving quality of life by reducing the often debilitating side-effects associated with systemic chemotherapy delivered intra-venously. Columbia University is the most recent trial site to join the Phase 3 study which continues enrolling patients at participating clinical sites across the U.S. "Cancer of the pancreas is aggressive and difficult to detect and treat," said Principal Investigator Susan Bates, M.D., Professor of Medicine at Columbia University Irving Medical Center. Dr. Bates added, "Treatment options have been limited to systemic chemotherapy for most patients. Local perfusion allows us to deliver much higher concentrations of an effective agent to the tumor. In the TIGeR-PaC trial, the tumor is temporarily isolated and saturated with gemcitabine, a well validated chemotherapeutic agent. In comparison to systemic chemotherapy treatment, RenovoRx has shown in its Phase 1/2 clinical trials that its therapy platform delivers a higher concentration of chemotherapy directly to the tumor with reduced patient side effects. This trial will offer a proof-of-principle that could establish direct delivery of chemotherapy as a strategy for treating pancreatic cancer in various settings." Dr. Ramtin Agah, RenovoRx's Founder and Chief Medical Officer, commented, "Dr. Bates and her Columbia University team share our deep commitment to helping pancreatic cancer patients. Enrolling our first patient at this renowned institution is an important milestone for the TIGeR-PaC clinical trial. This also gives more LAPC patients in New York, New Jersey and Connecticut an opportunity to participate in this study."

08:08 EST Genetic Technologies receives regulatory approvals for GeneType Multi-Test - Genetic Technologies is delighted to announce that on February 17, 2022 the Company's laboratory in Fitzroy, Melbourne has received simultaneous NATA accreditation and US Centers for Medicare and Medicaid Services CLIA-certification enabling the commercial launch of the GeneType Multi-Test in Australia and the USA, respectively. Highlights: Received simultaneous NATA accreditation & CMS certification for Multi-Test in Australia and USA respectively. Official first phase availability of Multi-Test to Health Care Professionals will occur week commencing February 21, 2022. First phase launch to cover risk assessment for six serious diseases including Breast, Colorectal, Prostate, and Ovarian Cancers, Coronary Artery Disease and Type-2 Diabetes covering more than 50% of all serious diseases, all in one test sample. Currently over 212,4001 individuals in Australia and 2.9 million individuals in the United States receive a diagnosis related to one of these six diseases annually. Multi-Test is protected by a robust family of patents.

08:05 EST Dirtt Environmental announces multiple initiatives to enhance performance - DIRTT Environmental Solutions announced multiple initiatives to enhance its performance as a preeminent industrialized construction company and reduce its fixed annualized operating expenses by approximately 14%. The Company is taking the following actions organized under its three strategic pillars: Innovation: DIRTT is introducing a Product Development filter designed to enable it to better focus on its suite of custom construction solutions, which provide clients greater certainty in cost, schedule, and outcomes, while delivering higher margin sales to the Company. The Company's proprietary ICE software plays a critical role for its partners and clients to envision and design their spaces. DIRTT will make new investments in ICE to include more core products and improve its ease of use. Manufacturing Excellence: The Company has adopted a new Master Facility Plan which is designed to deliver robust North American manufacturing capabilities in the East and West, with the goal of reducing shipping time and costs. As a first step, DIRTT will expand aluminum manufacturing at its facilities in Calgary, Alberta and Savannah, Georgia while closing its aluminum facility in Phoenix, Arizona. The move is expected to result in annualized cost savings of approximately $2.4 million. The Company is also expanding the capabilities of its Rock Hill, South Carolina panel plant to add Thermofoil panel and back-painted glass production, in addition to the plant's existing production of Chromacoat panels. DIRTT expects this will reduce shipping time and cost for Thermofoil panels to customers located in the East and Midwestern regions of North America, while leveraging the fixed cost base of the Rock Hill plant. The expansion is being achieved through the transfer of existing equipment from its facilities in Calgary and Phoenix and is not expected to incur any material capital costs. This is the first of several capability enhancements that were envisioned when the Rock Hill plant was launched last year. Following these changes, and assuming fully staffed manufacturing sites operating 24/7, the Company will have capacity to support annual sales of approximately $500 million at currently planned pricing and product mixes. Commercial Execution: Key drivers of the Company's 'go-to-market' strategy are being enhanced. The Company's Strategic Accounts group was established over two years ago and its work generates large commercial opportunities with leading organizations across North America. While this work can have a long lead time given its size and scope, once a client has committed to the DIRTT solution, it can result in repeat sales as the client replicates the same design standard across its network, often at an enormous cost saving. Recognizing the considerable value DIRTT adds during the pre-construction stage, particularly within the strategic accounts group, certain of those services will now be provided for a fee. DIRTT's commitment to its partner network is being reinforced through several initiatives. The Company is establishing a Partner Advisory Council to provide a greater link to its clients and partners. The Council will offer its advice on sales and marketing effectiveness, product issues and new market needs, market conditions, competitive landscape, marketing support and other related areas of mutual interest. The Company is altering its order entry process, which it anticipates will facilitate a reduction in standby production capacity. Effective May 1, 2022, DIRTT is changing its standard payment terms to 50% due on shipment, instead of on order. By separating its deposit requirement from the order entry process, management believes the Company can encourage earlier order entry and thereby reduce standby production labor capacity by up to 20%, while continuing to provide certainty in scheduling. The Company is announcing several initiatives regarding pricing. Effective June 1, 2022, it will introduce a 5% price increase in response to continued inflationary impacts to its material costs. DIRTT is also launching new aggressive pricing strategies on its Reflect and Inspire lines of glass wall products, with a view to capturing greater market share in this category, while offering an important entry point to explore the Company's broader construction solutions. Similarly, in looking to capitalize on the growing healthcare sector, DIRTT will also be launching an aggressive pricing program for applied headwalls as a compelling standalone product that works in harmony with the base building. As DIRTT identifies new market drivers, evolving customer needs and an opportunity to be a stronger partner to the design and build ecosystem, the Company is rebranding and repositioning DIRTT for future growth. The evolution of the Company and its value will be reflected in a shift from being a market disruptor to an enabler, with an emphasis on elevating clients and the outcomes they are able to achieve with DIRTT's construction system. With changes already underway, the formal rebrand will be launched in late Q2, supported by a new go-to-market strategy, new sales tools, a comprehensive digital experience, and national and regional campaign efforts. In addition to the changes aligned with the Company's strategy, DIRTT also announced the following developments: DIRTT is finalizing details of an organization-wide restructuring of positions that will contribute to the reduction of fixed expenses. These will take effect this quarter. The entire senior executive team have elected to receive 100% of their 2021 variable compensation in shares rather than cash. The Company's directors have each elected to receive 100% of their compensation under the Company's Deferred Share Unit Plan, rather than cash. DIRTT looks forward to welcoming its Calgary team back to the office and is launching a longer-term plan to create a new DIRTT Experience Center there, similar to what it opened in Dallas, Texas last year. The Dallas DXC is home to a versatile space that serves the diverse needs of the local team while also hosting a growing number of visitors looking to learn more about the Company's construction system. The Company also operates DXCs in Chicago, Illinois and New York, New York. Taken together, these changes are expected to reduce the Company's annualized fixed costs by approximately 14% as well as increase the efficiency of its variable costs. The Company continues to look for further ways to enhance its performance and benefit from the significant changes taking place in the market.

08:03 EST Health Catalyst to acquire KPI Ninja, terms not disclosed - Health Catalyst announced that it has entered into a definitive agreement to acquire KPI Ninja, a Lincoln, Nebraska-based provider of interoperability solutions and population health analytics. Health Catalyst expects KPI Ninja's ability to seamlessly ingest, aggregate, and analyze varied data sources from inside and outside the hospital, such as FHIR, Hl7 V2, CCDs, flat files, and APIs, will bolster Health Catalyst's existing data processing capabilities and maximize functionality of Health Catalyst's Analytics Applications layer. Health Catalyst is committed to enabling KPI Ninja's focus to be on continued outstanding execution and delivery to existing clients, with its current client support teams and relationships uninterrupted in enabling this focus and execution.

08:02 EST Orion Energy makes changes to certain executive compensation plans - Orion Energy Systems announced that the Compensation Committee of its Board of Directors, after careful consideration, has determined to make certain investor-friendly changes to some of its executive compensation plans. Specifically, Orion and its Chief Executive Officer and Board Chair, Mike Altschaefl, agreed to amend Mr. Altschaefl's so-called "single-trigger" change in control severance arrangement to a so-called "double-trigger" arrangement. Also, Orion's Compensation Committee has decided to change the structure of its annual grant of restricted stock awards to its executives, which occurs shortly after Orion announces its fiscal year-end financial results. Instead of awarding restricted stock that vests solely based on continued employment over a three-year period, the awards this coming fiscal year will be allocated between those that vest based on time and those that vest based on three-year performance criteria.

07:57 EST Westhaven Gold reports drill results from Shovelnose gold property - Westhaven Gold is pleased to announce drill results from its ongoing, fully-financed drill campaign at its 100% owned 17,623-hectare Shovelnose gold property. Shovelnose is located within the prospective Spences Bridge Gold Belt, which borders the Coquihalla Highway 30 kilometres south of Merritt, British Columbia. Gareth Thomas, President & CEO, comments: "Hole SNR21-55 is a completely new high-grade gold discovery within Vein Zone 2 at the Alpine Zone. This hole is approximately 500 metres from previous high-grade intercepts within Vein Zone 2 at the South Zone. This is very exciting as it remains open to the northwest and gives us a whole new area to focus on." Recent Drilling Highlights: SNR21-55: 8.00 metres of 20.22 g/t gold and 83.97 g/t silver, including 3.13m of 45.23 g/t Au and 195.64 g/t Ag. 17.00m of 1.02 g/t Au and 1.24 g/t Ag, including 3.00m of 5.25 g/t Au and 5.44 g/t Ag. SNR21-54: 27.52m of 0.68 g/t Au and 1.04 g/t Ag, including 3.00m of 4.84 g/t Au and 6.16 g/t Ag. SNR21-53: 73.24m of 0.39g/t Au and 2.91 g/t Ag, including 1.98m of 7.22 g/t Au and 15.34 g/t Ag.

07:54 EST Draganfly announces over 500,000 seats sanitized - Draganfly is pleased to announce that the Company has disinfected its 500,000th seat using its proprietary pathogen and surface sanitizer spray. In addition to the recent spraying at Alabama State University's Dunn-Oliver Acadome, Draganfly's proprietary pathogen and surface sanitizer spray was administered ahead of the Drone Racing League's Vegas Championship Race Presented by T-Mobile outside T-Mobile Arena during CES 2022 as well as the EDGE22 plenary sessions at the Park Theater in the Park MGM in Las Vegas, Nevada. Last year, the Company's spray was implemented ahead of several high-profile events, including NASCAR's June tripleheader weekend at the Nashville Superspeedway and Barrett-Jackson's March collector car auction in Scottsdale, Arizona.

07:50 EST Otonomy completes enrollment in Phase 2 trial of OTO-313 - Otonomy announced the completion of patient enrollment in the Phase 2 clinical trial of OTO-313 in tinnitus. The randomized, double-blind, placebo-controlled trial enrolled 153 patients with persistent, unilateral tinnitus of at least moderate severity. Patients were randomized 1:1 to a single intratympanic injection of OTO-313 or placebo and are being followed for 4 months. The primary endpoint is the same as reported for the successful Phase 1/2 trial: a responder analysis based on the proportion of patients who report a clinically meaningful improvement in the Tinnitus Functional Index from baseline to Months 1 and 2 following treatment. Top-line results for all timepoints are expected to be available in mid-2022.

07:47 EST Neuronetics announces amendment of credit facility with SLR Investment - Neuronetics announced it has amended its term loan agreement with its current lenders, investment affiliates managed by SLR Investment, which was originally entered into on March 2, 2020 and subsequently amended on April 20, 2020 and December 2, 2020. This amendment includes modifications to the ability of the Company to extend the interest-only period, the reduction of certain revenue covenants, and the elimination of the final term loan tranche available to the Company. The Company has the ability to, subject to certain conditions, extend the interest only period on the initial Term A Loan to 36 months from 24 months, which if such conditions are satisfied, would allow for the commencement of loan principal amortization payments beginning on March 1, 2023. In addition, the amendment reduced the trailing twelve-month net product revenue covenants related to the facility. As part of the December 2, 2020 amendment, the Company was permitted to borrow, at its election, up to $15.0 million in three separate $5.0 million tranches. The three tranches were available through June 20, 2021, December 20, 2021, and June 20, 2022, respectively, based on the achievement of agreed upon trailing twelve-month net product revenue targets for each tranche. The Company previously elected not to draw either of the Term B or Term C tranches, and, as part of this amendment, the Company agreed that it would not draw the Term D tranche.

07:46 EST Healthcare Capital, Alpha Tau announce stockholder approval for combination - Healthcare Capital and Alpha Tau Medical announced that in its special meeting held on February 18, 2022, HCCC's stockholders voted to approve the previously announced proposed business combination of HCCC and Alpha Tau. Approximately 94.57% of the votes cast at the meeting, representing approximately 65.64% of HCCC's outstanding shares as of the record date, voted to approve the Business Combination. In addition, HCCC's stockholders approved all other proposals put before stockholders at the special meeting. Upon consummation of the Business Combination, the combined company will operate as Alpha Tau Medical Ltd. and its ordinary shares and warrants are expected to trade on NASDAQ under the new symbols "DRTS" and "DRTSW," respectively.

07:43 EST Microbix Biosystems nominates Jennifer Stewart to board of directors - Microbix Biosystems announces that Jennifer Stewart government, and public affairs, has been nominated to become a member of its Board of Directors. If appointed by a majority of shareholders voting at Microbix's Annual General Meeting on Wednesday, March 30, 2022, Ms. Stewart will join the Board of Directors and will also be asked to serve as a member of the Human Resources, Compensation & Governance Committee. Ms. Stewart is founder, President, and CEO of Syntax Strategic a leading firm in the sector of advocacy and communication for the public and private sectors.

07:42 EST Meritor trading resumes

07:40 EST KKR to acquire majority stake in Refresco, terms undisclosed - Refresco Group and KKR announced that KKR has signed a definitive agreement to acquire a majority stake in Refresco, with Refresco's existing investors, PAI Partners and British Columbia Investment Management Corporation, or BCI, maintaining a significant minority position. Terms of the transaction, which is subject to closing conditions, were not disclosed. Founded in 1999, Refresco is a global independent beverage solutions provider for retailers and branded beverage companies with pan-regional coverage in Europe and North America through its network of bottling, warehousing, logistics and other operational assets. The company's production platform includes over 70 majority-owned manufacturing sites in Europe, the U.S., Canada and Mexico, providing customers with close proximity and a reliable service across geographies.

07:38 EST Jushi Holdings announces cannibs brands, product launches in Massachusetts - Jushi Holdings announced a series of upcoming launches of branded cannabis products in the Commonwealth of Massachusetts, beginning with the debut of its flower brands, The Bank and Seche. The Company is also expected to launch its vaporizable cartridges & jarred concentrates line, The Lab, and its edibles line, Tasteology, in the second quarter of 2022, pending regulatory approval. Jushi's brands will be available for purchase at its subsidiary, Jushi MA, Inc. d/b/a Nature's Remedy of Massachusetts in Tyngsborough and Millbury, Massachusetts, and has plans to roll out to the more than 190 partner dispensaries across the Commonwealth. In Massachusetts, Jushi's award-winning brand, The Bank, is known for its superior plant genetics and next-level cultivation. The brand has been fully reimagined and designed for the modern, discerning cannabis connoisseur. The Bank offers pre-packaged 3.5g glass jars of flower in three-tiered lines: Gold Standard, Cache and Vault, as well as infused and non-infused Blunts. Today, The Bank is available at Nature's Remedy retail locations in Tyngsborough and Millbury, as well as at dispensaries across Pennsylvania, Nevada, Virginia, and Ohio, pending regulatory approval. Seche boldly invents a new category in cannabis by redefining the perception of value products like shake and popcorn. With a carefree spirit and the curiosity to uncover what's next, Seche invites you on a yet unwritten adventure. With products like Kind Grind infused 14g jarred flower and 1g infused pre-rolls, Fine Grind, Fine Flower, 5 pre-rolled joint Multipack, Singles and All Day. Seche is available at Nature's Remedy stores in Tyngsborough and Millbury as well as at dispensaries across Pennsylvania, Nevada, Virginia, and Ohio. The Company will also be rolling out Seche products to partner dispensaries across Massachusetts, pending regulatory approval. The Lab is an award-winning brand famous for its high-quality, precision vape products and concentrates. Through cutting-edge technology and equipment, The Lab continues to lead the way in bringing the unique experience of cannabis to new and modern mediums. Jushi plans to bring The Lab's award-winning, high-quality 0.3g all-in-one vape, 0.5g vape cart, cured jarred concentrates, live and solventless jarred concentrates in various varieties to patients and consumers in the Bay State. Jushi's vapes and concentrates line will roll out to Nature's Remedy's locations and partner dispensaries in Massachusetts in the second quarter of 2022, pending regulatory approval and is currently available at dispensaries across Nevada, Virginia, and Ohio. In Massachusetts, Jushi plans to launch Tasteology, a brand of premium, real-fruit, cannabis-infused edibles and chocolates, pending regulatory approval. The unique combination of flavor and texture of Tasteology cannabis-infused edible products makes them especially well-suited to several consumer and patient populations. These edible products will be available in Blueberry Calm, Balanced Peach and Mango-Pineapple Boost varieties. The chocolate line will initially be available in milk, dark and strawberry blonde flavors. Tasteology products are expected to launch in Massachusetts in the second quarter of 2022, pending regulatory approval and currently can be purchased at dispensaries across Nevada, Virginia, and Ohio. Nira + Medicinals is expected to initially bring high-quality THC and CBD-rich medical tincture products to Massachusetts patients and consumers, pending regulatory approval. Nira +'s full suite of products, which includes tinctures, capsules, softgels and topicals, is expected to launch at Nature's Remedy retail locations and partner dispensaries in Massachusetts in the second quarter of 2022, pending regulatory approval and is currently available at dispensaries across Virginia.

07:37 EST Turning Point Brands enters deal for exclusive distribution of Clipper lighters - Turning Point Brands announced that it has entered into an agreement with Flamagas, a renowned lighter manufacturer, for exclusive distribution of Clipper lighters in the United States and Canada.

07:36 EST Gracell reports advancements of TruUCAR CAR-T cell platform - Gracell announced multiple advancements of its TruUCAR platform, the company's proprietary technology platform designed to generate high-quality allogeneic CAR-T cell therapies that can be administered "off-the-shelf" as stand-alone therapy. An abstract providing early results of a first-in-human clinical study on GC502 in r/r B-ALL patients has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2022. GC502 is an allogeneic CD19/CD7 dual-directed CAR T cell therapy currently under development for multiple indications including B-ALL. GC502 is currently being studied in a Phase 1 investigator-initiated trial in China for patients with B-cell malignancies. Another lead product candidate of the TruUCAR platform is GC027, an allogeneic CAR-T therapy targeting CD7 for the treatment of adults with T-cell lymphoblastic leukemia. Gracell is currently investigating GC027 in a Phase 1 IIT study in China evaluating the safety and efficacy. Both GC502 and GC027 are poised to strengthen the allogeneic platform approach of TruUCAR.

07:35 EST Oyster Point Pharma announces TYRVAYA nasal spray covered by Express Scripts - Oyster Point Pharma announced TYRVAYA Nasal Spray's placement on the Express Scripts National Preferred, Basic, and High Performance Formularies, which collectively makes up an estimated 26 million lives, effective February 19, 2022. TYRVAYA is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease.

07:34 EST Cummins to acquire Meritor for $36.50 p/s in cash

07:32 EST Provention Bio resubmits BLA for teplizumab to FDA to address CRL - Provention Bio announced it has resubmitted the Biologics License Application for teplizumab for the delay of clinical type 1 diabetes in at-risk individuals. The purpose of the resubmission is to address the FDA's pharmacokinetic comparability considerations contained in the complete response letter issued last July, as well as the CRL's Chemical, Manufacturing, and Controls and product quality considerations. The CRL did not cite any clinical deficiencies related to the efficacy and safety data packages submitted to the original BLA. The resubmission comes after last month's Type B meeting at which the FDA proposed, and the company agreed, to use PK modeling to adjust the 14-day dosing regimen for the planned commercial product to match the exposure of clinical material used in prior clinical trials by ensuring that the 90% confidence intervals for relevant PK parameters fall within the target 80-125% range. Under applicable FDA guidelines, the FDA has 30 days to review the resubmission, determine whether it is complete and acceptable for review, and provide a review goal date.

07:29 EST Else Nutrition concludes preclinical study on Plant-Based infant formula - ELSE NUTRITION HOLDINGS is pleased to announce that it has concluded a successful preclinical study on its Plant-Based infant formula, on the pathway to bring its formulation to market This marks a key first step on the path with the Food and Drug Administration, as well as with other regulatory authorities, to demonstrate safety and nutrient bioavailability of the Else infant formula. The study results demonstrated proper growth similar to a dairy-based infant formula, in a neonatal preclinical model. The full study results will be presented at an international scientific conference on pediatric nutrition and growth in March 2022.

07:27 EST Flora Growth registers cannabinoid food and beverage products with Colombian-FDA - Flora Growth announced that the Company has filed twenty-three cannabinoid-infused food and beverage products with the Instituto Nacional de Vigilancia de Medicamentos y Alimentos INVIMA, similar to the U.S. FDA. This announcement comes as Colombian President, Ivan Duque, signed Resolution 227, which provides the necessary framework for the use, distribution and export of cannabis, dried flower, and other non-psychoactive derivatives. Flora expects to be the first cultivator in the world to obtain these unique approvals from INVIMA for its cannabinoid-infused food and beverage products which will include juices, sparkling seltzers, gummies, and healthy snack foods. These goods have been developed under Flora's KASA Wholefoods division which prioritizes the sourcing of natural ingredients and value-chain sustainability to create items to help consumers restore and thrive. "We are incredibly excited by the government's decision to permit cannabinoid food and beverage products and look forward to bringing these cannabis wellness products to consumers in Colombia and around the globe," said Luis Merchan, President and CEO of Flora Growth. "Aligning with globally recognized safety and compliance standards is at the forefront of Flora's strategy, particularly when it comes to the food and beverage sector of the cannabis industry."

07:27 EST Lottery.com partners with T-Mobile as digital lottery brand for in-vehicle ads - Lottery.com (LTRY) announced that it has signed an agreement with T-Mobile (TMUS) to become the exclusive digital lottery brand for in-vehicle advertising. Lottery.com will work with Marketing Solutions, T-Mobile's fast-growing ad technology business, to reach audiences through video ads presented on screens inside rideshare vehicles, where user rides average approximately fifteen minutes. As part of the agreement, Lottery.com has the right as the exclusive digital lottery brand to execute comprehensive geo-targeted campaigns across a range of highly engaged consumers in jurisdictions where Lottery.com offers its services. As Lottery.com enters new states in the U.S., the parties anticipate that this exclusive advertising arrangement will also expand.

07:26 EST TEGNA trading halted, news pending

07:25 EST Macy's jumps 8% to $27.75 after Q4 results, FY22 guidance beat estimates

07:24 EST SweetWater Brewing announces distribution rollout across Washington, Oregon - SweetWater Brewing Company has announced its continued westward expansion into both Washington and Oregon, with distribution partner Columbia Distributing, keeping up the momentum after the announcement of its launch into California earlier this month. With this multi-state expansion, SweetWater continues to hit major milestones as it celebrates its 25th anniversary this year, with the opening of SweetWater Colorado Brewing Company, LLC, it's new brewery and taproom location in Fort Collins, Colorado, and the recent acquisition of classic craft beer brands Alpine Beer Company and Green Flash Brewing Co. SweetWater Brewing in partnership with Columbia Distributing will bring its core line of quality craft brews throughout both states, including its flagship SweetWater 420 Extra Pale Ale, H.A.Z.Y. IPA, and 420 Imperial IPA, in addition to its rotating variety packs featuring a variety of other heady brews, into local restaurants and bars, grocery chains, liquor stores and other retail establishments. The expansion into Washington and Oregon marks the 39th and 40th states respectively, where SweetWater products will now be available for purchase.

07:22 EST BioCryst begins patient enrollment in RENEW PoC trial for BCX9930 - BioCryst Pharmaceuticals announced the enrollment of the first patient in the RENEW proof-of-concept basket study with its oral Factor D inhibitor, BCX9930, in patients with C3 glomerulopathy, immunoglobulin A nephropathy and primary membranous nephropathy. RENEW is an open-label, multicenter, proof-of-concept study designed to evaluate the safety, tolerability and therapeutic potential of BCX9930 administered for 24 weeks in approximately 42 adult patients with either C3G, IgAN or PMN. All patients will be enrolled into one of three parallel study cohorts, based on confirmation of diagnosis and disease activity in a recent kidney biopsy, and will receive BCX9930 for the 24-week treatment period. The primary endpoint of RENEW is percent change from baseline in 24-hour urine protein-to-creatinine ratio, as assessed at week 24. For more information about RENEW, visit ClinicalTrials.gov and search NCT number NCT05162066. BioCryst recently announced it has begun enrolling patients in the REDEEM-1 and REDEEM-2 pivotal trials evaluating BCX9930 for patients with PNH. REDEEM-1 is a randomized, open-label, active comparator-controlled study of the efficacy and safety of oral BCX9930 monotherapy in PNH patients with an inadequate response to a C5 inhibitor. REDEEM-2 is a randomized, placebo-controlled study to evaluate the efficacy and safety of oral BCX9930 as monotherapy versus placebo in PNH patients not currently receiving complement inhibitor therapy. BioCryst plans to further advance and expand its Factor D program over the next two years by achieving the following: Complete and report data from REDEEM-1 and REDEEM-2; Prepare to submit regulatory approval filings in PNH; Complete the RENEW PoC basket trial and advance to pivotal trials in C3G, IgAN and PMN; Commence PoC trials in other complement-mediated diseases

07:20 EST Renalytix appoints Timothy Scannell to board of directors - Renalytix announced its intention to appoint Timothy Scannell to its board of directors as an independent non-executive director. Mr. Scannell currently serves as Chair of Insulet Corporation's board of directors and serves on the board of directors for Novocure and Collagen Matrix.

07:19 EST MediciNova's MN-166 identified as pharmacotherapy for alcohol use disorder - MediciNova announced MN-166 - ibudilast - was discussed as one of the promising pharmacological agents for the treatment of alcohol use disorder in the journal Drugs. The publication identified drug candidates with potential clinical utility, and among the many compounds reviewed, named MN-166 - ibudilast - as one of the promising treatments for AUD with clinical findings that warrant further investigation for the treatment of this highly prevalent, chronic, and relapsing condition. Preclinical findings that demonstrate that MN-166 reduces alcohol intake align with prior studies in which pharmacological inhibition of PDE also reduced alcohol intake. MN-166 improves mood during exposure to alcohol and stress cues, and reduces the mood-altering and stimulant effects of alcohol among participants with more severe depressive symptoms. MN-166 reduces alcohol craving on non-drinking days, reduces the odds of heavy drinking by 45%, and attenuates neural response to alcohol cues. MN-166 appears to be well tolerated.

07:17 EST FDA accepts NDA for Harrow Health's AMP-100 for surface anesthesia - Harrow Health announced that the U.S. Food and Drug Administration FDA has accepted the New Drug Application filing for AMP-100, the Company's drug candidate for ocular surface anesthesia and intraoperative pain management during ocular surgery. The FDA has assigned the application standard review and a Prescription Drug User Fee Act PDUFA target action date of October 16. In commenting on the announcement, Mark L. Baum, Chief Executive Officer of Harrow Health, said, "The FDA's acceptance of the AMP-100 NDA is a major step forward for Harrow Health Inc. and our commitment to make this patented, innovative drug candidate available. The non-opioid active pharmaceutical ingredient used in AMP-100, if approved, would be the first approved use of this ingredient in the U.S. ophthalmic market. We look forward to working with the FDA during the review process, and we are excited about making AMP-100, if approved, commercially available to the thousands of ophthalmologists, optometrists, hospitals, and ambulatory surgery centers we serve throughout the United States."

07:16 EST Akoustis receives 5G mobile XBAW filter development order - Akoustis Technologies announced that it has signed a statement-of-work / development order from a leading tier-1 RF module maker and filter provider for a new 5G mobile XBAW filter.

07:14 EST XPO Logistics expands field management training in LTL business - XPO Logistics announced the expansion of its less-than-truckload Field Management Trainee Program, with a goal of graduating 100 participants in 2022. The comprehensive curriculum creates career paths for high-potential hourly employees, military veterans and recent college graduates, positioning them for promotion. XPO's recent investments in the program extend the training from 12 to 14 weeks, blend e-learning and in-person instruction, and assign a mentor to each trainee. Participants are immersed in XPO's North American LTL business, where they learn the operations for outbound and inbound shipping, pickup-and-delivery and freight assembly. Trainees also shadow sales and support functions, receive freight leadership certification and attend a technology summit. Upon successful completion of the program, participants are qualified to become LTL freight operations supervisors as the next step toward potential field management roles. The company provides competitive, full-time pay and benefits from day one of the program.

07:13 EST Macy's reports Q1 digital sales up 12% y/y, up 36% vs. 4Q19 - Digital penetration was 39% of net sales, a 5-percentage point decline from the fourth quarter of 2020, but a 9-percentage point improvement over the fourth quarter of 2019.

07:12 EST Karyopharm Chief Medical Officer, Jatin Shah, M.D., steps down - Karyopharm Therapeutics announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management. In addition, Jatin Shah, M.D. Executive Vice President and Chief Medical Officer has stepped down to pursue other professional opportunities, but will continue to serve Karyopharm in an advisory capacity. The company is in the process of evaluating candidates to fill the Chief Medical Officer position.

07:11 EST Churchill Downs to acquire Peninsula Pacific Entertainment for $2.485B - Churchill Downs Incorporated announced that the Company has entered into a definitive purchase agreement to acquire substantially all of the assets of Peninsula Pacific Entertainment for total consideration of $2.485B. CDI will acquire all of P2E's assets in Virginia and New York as well as the operations of its Sioux City casino property. The P2E Transaction is dependent on usual and customary closing conditions, including the Company obtaining approvals from the Virginia Racing Commission, the New York State Gaming Commission, and the Iowa Racing and Gaming Commission. The transaction is expected to close by the end of 2022. CDI will acquire Colonial Downs Racetrack, a Thoroughbred racing facility in New Kent, Virginia, as well as six successful and growing "Rosie's Gaming Emporium" historical horse racing facilities across Virginia. Rosie's Gaming Emporium locations currently include Collinsville, Dumfries, Hampton, New Kent, Richmond and Vinton. These facilities currently have approximately 2,700 historical racing machines. The transaction significantly expands the geographic diversity of CDI's live and historical racing entertainment venues and reinforces CDI's role as a national leader in historical horse racing. CDI will acquire del Lago Resort & Casino in Waterloo, New York. del Lago is a 96,000 sq. ft. casino with approximately 1,700 slot machines, 80 table games, a 205-room hotel, nine restaurants / bar areas, 758 covered parking spaces, a 6,000 sq. ft. sportsbook area, a 2,400-seat entertainment venue, and a 7,200 sq. ft. outdoor event venue. CDI will acquire the operations of Hard Rock Hotel & Casino in Sioux City, Iowa. Hard Rock Sioux City is a 45,000 sq. ft. casino with 639 slot machines, 20 table games, a 54-room hotel, 1,511 parking spaces with 530 covered, two live entertainment venues, a 100-piece music memorabilia collection, and a Hard Rock-branded sportsbook. Under the terms of the P2E Transaction, P2E is expected to reach a definitive agreement to sell the real property associated with Hard Rock Sioux City to a third party. CDI will acquire the operating company and lease the Sioux City Property from that third party. Following the closing, CDI will operate Hard Rock Sioux City and lease the Sioux City Property pursuant to lease terms negotiated prior to the closing. In the event P2E is unsuccessful in reaching a definitive agreement with a third party to purchase the Sioux City Property by a certain date, the Sioux City Property will be included in the P2E Transaction and the total consideration will increase to $2.75B. Under Virginia law, CDI will have the opportunity to develop up to five additional historical racing entertainment venues in Virginia with collectively up to approximately 2,300 additional HRMs. As part of the P2E Transaction, CDI will also acquire the rights to build a large gaming resort, with up to 1,800 HRMs in Northern Virginia. P2E previously announced plans to invest up to $400 million to build the initial phase of the Dumfries Project, which is scheduled to open in 2023. CDI will also acquire the rights to develop Rosie's Gaming Emporium in Emporia, the seventh historical racing entertainment venue under P2E's Colonial Downs license. The Emporia facility, located along I-95 near the North Carolina border, will have 150 HRMs and is expected to open in 2023. Also, included in the P2E Transaction are the rights to P2E's ongoing effort in partnership with Urban One, to develop ONE Casino + Resort, a $565 million destination casino in Richmond, Virginia. P2E's gaming license in the State of Louisiana, and its casino development rights in Cedar Rapids, Iowa, are not included in the transaction. The P2E Transaction purchase price represents a multiple of less than 9.0x Adjusted EBITDA. This purchase price multiple includes the incremental value from the recent opening and expansion of certain Virginia facilities and the incremental value that CDI expects to realize from the acquisition of the development rights related to historical horse racing in Virginia. For tax purposes, the acquisition will be treated as an asset purchase allowing CDI to realize incremental tax benefits which will provide additional cash flow and will enhance the overall economics of the transaction. he P2E Transaction is expected to be immediately accretive to CDI's free cash flow and diluted earnings per share. CDI will fund the P2E Transaction with a combination of new debt and cash on hand including pending proceeds from the sale of land near Calder Casino. Consolidated proforma bank covenant leverage is projected to be less than 4.2x upon completion of the P2E Transaction. As previously disclosed, the Company is planning to use the proceeds from its pending sale of land near Calder Casino to structure aspects of this acquisition as an Internal Revenue Code Section1031 transaction to defer the tax on the gain on sale.

07:09 EST FDA accepts sNDA for BeiGene's BRUKINSA for CLL treatment - BeiGene announced that the U.S. Food and Drug Administration, FDA, has accepted a supplemental new drug application, sNDA, for BRUKINSA or zanubrutini, for the treatment of adult patients with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. CLL is the most common form of adult leukemia. The Prescription Drug User Fee Act target action date is October 22 "We are pleased with the FDA's acceptance of BRUKINSA's filing in CLL. This is an important milestone in BRUKINSA's global registration program. With superiority in investigator-assessed ORR over ibrutinib in ALPINE for relapsed or refractory patients and in PFS over chemoimmunotherapy in the SEQUOIA study for treatment-naive patients, BRUKINSA has demonstrated its potential to improve treatment outcomes for CLL patients," commented Jane Huang, M.D., Chief Medical Officer of Hematology at BeiGene. "We look forward to furthering our discussions with the FDA on this filing and the potential to bring this important treatment option to the CLL community in the U.S."

07:09 EST Esperion sees FY22 operating expenses $220M-$240M - Research and Development expenses for the full year 2022 are expected to be $100 million to $110 million. Selling, General and Administrative expenses for the full year 2022 are expected to be $120 million to $130 million. Esperion expects full-year 2022 operating expenses to be approximately $220 million to $240 million, inclusive of $25 million of non-cash, stock-based compensation expense.

07:06 EST CI Financial to acquire Corient Capital Partners, terms not disclosed - CI Financial announced an agreement under which CI will acquire Corient Capital Partners, a Newport Beach-based wealth management firm overseeing $5B on behalf of ultra-high-net-worth individuals and families across the United States. The transaction is expected to close in the second quarter of 2022, subject to regulatory approvals and other customary closing conditions.

07:03 EST Carrier updates medium-term value creation framework ahead of investor day - Carrier Global is hosting its 2022 investor day at the Center for Intelligent Buildings, beginning at 8:30 a.m. ET. In conjunction with the announcement, the company is updating its medium-term value creation framework. The company expects organic sales up 6%-8%. Expects annual gross cost productivity up 2%-3%. Expects adjusted operating margin expansion of more than 50 bps per year. Expects double-digit growth in adjusted EPS. Expects free cash flow conversion of 100%.

06:55 EST Dillard's sees 2022 CapEx $150M from $104M in 2021

06:49 EST IGT Global Solutions signs three-year contract extension with Missouri Lottery - International Game announced that its subsidiary, IGT Global Solutions, has signed a three-year contract extension with long-time partner, the Missouri Lottery, which extends the existing agreement until June 30, 2025. As part of this agreement, IGT will deploy 175 new cashless GameTouch 28 self-service vending machines, expanding the Lottery's retailer base and allowing for a more dynamic user experience among players. IGT will also support the Lottery's launch of IGT's highly proprietary Cash Pop draw game.

06:43 EST Tempur Sealy increases quarterly dividend to 10c per share - Tempur Sealy announced that its board of directors has declared a first quarter cash dividend on its common stock of 10c per share. The dividend is payable on March 22 to shareholders of record as of March 8.

06:39 EST InfuSystem announces national distribution agreement with Solo-Dex - InfuSystem announced a national distribution agreement with Solo-Dex for its proprietary continuous nerve block catheters.

06:37 EST Vontier announces $250M accelerated share repurchase agreement - Vontier announced that it has entered into a $250M accelerated share repurchase agreement with Citibank. Vontier will acquire the shares as part of its previously approved $500M share repurchase authorization announced in May 2021.

06:28 EST SoFi Technologies: Technisys acquisition to accelerate three-year revenue CAGR - The acquisition will also add to the high revenue growth rate of SoFi and accelerate its three-year revenue CAGR. Together, the companies can better serve Galileo's consumer fintech and enterprise partners seeking to add product offerings to their 89 million enabled customer accounts across the U.S., Mexico and Colombia, and Technisys' more than 60 established bank, fintech, and non-financial brands in Latin America and the U.S., while expanding both companies' partner bases in the U.S. and an addressable market across 16 countries. The estimated incremental revenue from the acquisition, including base revenue of Technisys and revenue synergies of the vertically integrated capabilities, is expected to add a cumulative $500 to $800 million through year-end 2025, at high incremental margins. SoFi also expects to leverage this modern technology stack to capture significant savings in third-party costs by integrating Technisys. Once SoFi has migrated off its current multiple third-party cores to a single owned and operated Technisys core, it expects to be able to innovate even faster, perform more real-time decisioning, and offer greater personalization for its more than three million members. SoFi estimates this shift and the vertical integration with Galileo will create approximately $75 to $85 million in cumulative cost savings from 2023 to 2025 and approximately $60 to $70 million annually thereafter. Technisys' revenue growth is accelerating and is on track to deliver approximately $70 million in revenue for calendar-year 2021 on an unaudited IFRS basis. The acquisition is expected to deliver to SoFi a mid-teens internal rate of return on a standalone basis through 2025, with significant upside in the IRR when accounting for anticipated revenue and cost synergies.

06:21 EST Houghton Mifflin to be acquired by Veritas Capital for $21.00 per share - Houghton Mifflin announced that it has entered into a definitive merger agreement with certain affiliates of Veritas Capital, a private investment firm, for the acquisition of the company. Pursuant to the terms of the agreement, HMH shareholders will be entitled to receive $21.00 in cash per share through a tender offer. The per share purchase price represents a 36% premium to the company's unaffected share price as of January 13 and implies an equity value of approximately $2.8B. The agreement was unanimously approved by HMH's board of directors. The transaction is expected to be completed in Q2, subject to receipt of requisite regulatory approvals and satisfaction of customary closing conditions.

06:19 EST Hercules Capital announces new supplemental cash distribution of 60c per share - Hercules Capital is pleased to announce that its Board of Directors has declared a new supplemental cash distribution of 60c per share, to be distributed equally over four quarters beginning with a 15c per share distribution for the fourth quarter of 2021.

06:17 EST Centerra Gold acquires Goldfield District development project in Nevada - Centerra Gold has entered into a definitive agreement whereby Centerra, through its subsidiary Centerra U.S., will acquire 100% of Gemfield Resources, owner of the Goldfield District Project from Waterton Nevada Splitter, for $206.5M - S$175M in cash at closing plus a $31.5M future milestone payment payable in cash or Centerra shares. Goldfield is a conventional open-pit, heap leach project in late-stage development, located in a Tier 1 mining jurisdiction. Centerra believes that the project has significant upside potential from its large, underexplored land position in an established mining area in Nevada that has produced more than 4 million ounces of gold historically. Goldfield is anticipated to add meaningful future low-cost production to Centerra with a conventional open-pit heap leach mine with expected low capital intensity, similar to that of our operational Oksut Mine in Turkey. The acquisition provides an anchor asset that can act as a foothold for further opportunities in the United States. Centerra currently has five active exploration joint ventures in the United States and six in Canada. The company plans to further refine existing technical studies undertaken to date by Waterton, with a resource estimate expected to be released in the first half of 2023 and an updated feasibility study thereafter. Centerra has identified numerous targets for drill-ready regional exploration, with the potential to expand known deposits and extend mine life.

06:13 EST Home Depot reports Q4 comparable sales up 8.1% - Reports Q4 U.S. comparable sales up 7.6%

06:12 EST BrightView acquires Intermountain Plantings, terms not disclosed - BrightView Holdings announced the acquisition of Intermountain Plantings, a commercial landscaping company headquartered in Salt Lake City. Terms of the transaction were not disclosed.

06:10 EST Northwest Natural Gas acquires two utilities in Southern Texas - Northwest Natural Holding's wholly-owned subsidiary NW Natural Water signed two agreements to acquire utilities in Southeast Texas, expanding the company's footprint in the region. NW Natural Water subsidiaries have executed agreements to acquire assets of Water Necessities & Rural Water near Beaumont, Texas and Caney Creek Utilities in Montgomery, Texas. The acquisitions are subject to customary closing conditions, including approval by the Public Utility Commission of Texas, and are expected to close in 2022. When all pending acquisitions close, NW Natural Water will serve over 145,000 people through approximately 60,000 connections in Oregon, Washington, Idaho, Texas and Arizona.

06:07 EST RBB Bancorp CEO Alan Thian to take leave of absence, Morris named interim CEO - RBB Bancorp announced that President and CEO Alan Thian will take a leave of absence, effective immediately, pending an internal investigation being conducted by a special committee of the RBB Board of Directors. The RBB Board of Directors has appointed David Morris, Executive Vice President and CFO, as Interim President and CEO. Morris will continue in his role as CFO.

06:02 EST SoFi Technologies to acquire Technisys for $1.1B - SoFi Technologies announced that it has entered into a definitive merger agreement to acquire Technisys, a cloud-native, digital multi-product core banking platform. Technisys' shareholders will receive aggregate consideration of approximately 84M shares of SoFi common stock, less than 10% of SoFi's fully diluted share count as of September 30, 20211, subject to customary adjustments set forth in the Merger Agreement. These shares have an aggregate value of approximately $1.1B based on the volume weighted average price of SoFi common stock for the 20-trading day period ended February 15, 2022. The transaction is expected to close by the second quarter of 2022, subject to the satisfaction of closing conditions.

05:38 EST APA Corp. sees FY22-FY24 capital investment $5B - The company said, "Based on the current pricing outlook, in 2022, APA plans to invest $1.6 billion in upstream oil and gas capital, which includes approximately $200 million dedicated to exploration and appraisal activities, primarily in Suriname. In aggregate, capital investment will approximate $5 billion from 2022 to 2024. This capital spend should return the company to around 2019, pre-Covid production levels on an adjusted basis in 2024."

05:09 EST Hecla Mining sees FY22 silver production 12.9M-13.5M ounces - Sees FY22 gold production 125.000-132,000 ounces. Sees FY22 capital expenditures $135M.